skxrena personal page - To The Moon

skxrena

skxrena

No personal profile

364Follow

1Followers

0Topic

0Badge

2021-09-18

booooo

FDA Advisory Committee Votes Unanimously in Favor of COMIRNATY® Booster for Emergency Use in People 65 and Older and Certain High-Risk Populations

2021-09-15

go go go

Apple's new iPhone 13 touts faster 5G, sharper cameras to spur trade-ins

2021-08-31

up please!

Sorry, the original content has been removed

2021-08-26

good

S&P 500, Nasdaq notch all-time closing highs ahead of Jackson Hole

2021-07-30

cool

Sorry, the original content has been removed

2021-07-23

awesoms

Sorry, the original content has been removed

2021-07-21

great!

Sorry, the original content has been removed

2021-07-14

awesome

Apple shares rises nearly 1% in premarket trading.

2021-07-12

good

Toplines Before US Market Open on Monday

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":"4088497713200830","uuid":"4088497713200830","gmtCreate":1625394650107,"gmtModify":1626833819555,"name":"skxrena","pinyin":"skxrena","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/bcd0597b7a18627a33a524d8ac6dd51d","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":1,"headSize":364,"tweetSize":9,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.04.01","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.29","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"972123088c9646f7b6091ae0662215be-1","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Elite Trader","description":"Total number of securities or futures transactions reached 30","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.29","exceedPercentage":"60.42%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":4,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":3,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":887905534,"gmtCreate":1631952660528,"gmtModify":1676530677375,"author":{"id":"4088497713200830","authorId":"4088497713200830","name":"skxrena","avatar":"https://static.tigerbbs.com/bcd0597b7a18627a33a524d8ac6dd51d","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4088497713200830","idStr":"4088497713200830"},"themes":[],"htmlText":"booooo","listText":"booooo","text":"booooo","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/887905534","repostId":"2168957763","repostType":4,"repost":{"id":"2168957763","pubTimestamp":1631950800,"share":"https://ttm.financial/m/news/2168957763?lang=&edition=fundamental","pubTime":"2021-09-18 15:40","market":"us","language":"en","title":"FDA Advisory Committee Votes Unanimously in Favor of COMIRNATY® Booster for Emergency Use in People 65 and Older and Certain High-Risk Populations","url":"https://stock-news.laohu8.com/highlight/detail?id=2168957763","media":"StreetInsider","summary":"Committee reviewed clinical data showing a booster dose of COMIRNATY® elicits high neutralization ti","content":"<ul>\n <li><i>Committee reviewed clinical data showing a booster dose of COMIRNATY® elicits high neutralization titers against SARS-CoV-2 and all currently tested variants </i></li>\n <li><i>Reactogenicity profile within seven days of the booster dose was typically mild to moderate, with frequency of reactions similar to or lower than after the primary vaccination series</i></li>\n <li><i>Real-world data presented by Israel Ministry of Health show additional protection after receiving a</i> <i>booster translated to vaccine effectiveness comparable to levels seen early in the country’s vaccine</i> <i>rollout</i></li>\n <li><i>FDA expected to make its decision in the coming days </i></li>\n</ul>\n<p><b>NEW YORK AND MAINZ, GERMANY, September 17, 2021</b>—Pfizer Inc. (NYSE: PFE) and <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> (Nasdaq: BNTX) announced today that the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted unanimously to recommend the FDA grant Emergency Use Authorization (EUA) for a booster dose of COMIRNATY® (COVID-19 Vaccine, mRNA) in individuals 65 years of age and older and individuals at high risk of severe COVID-19. The committee recommended that the additional dose be administered at least six months after the two-dose series. The panel also agreed that healthcare workers and others at high risk for occupational exposure should be included in this EUA.</p>\n<p>VRBPAC is made up of independent experts who advise the FDA on scientific and regulatory matters, including the evaluation of vaccine safety and efficacy.</p>\n<p>At this time, VRBPAC did not vote in favor of approval of a booster dose for the full population for which Pfizer and BioNTech submitted their supplemental Biologics License Application, which was individuals 16 and older. The same data have recently been submitted to the European Medicines Agency (EMA) and will be filed with other regulatory authorities in the coming weeks. The companies remain vigilant and continue to generate relevant COMIRNATY booster dose data for evaluation for future licensure in further groups as well as to address emerging variants of concern.</p>\n<p>The FDA is expected to make its decision in the coming days. This decision could allow COMIRNATY to be the first COVID-19 vaccine with a booster authorized in the U.S.</p>\n<p>“Today the VRBPAC reviewed data from our clinical program showing a favorable safety profile and strong immune responses against SARS-CoV-2 after a booster dose of our vaccine. These data, and the larger body of scientific evidence presented at the meeting, underscore our belief that boosters can be a critical tool in the ongoing effort to control the spread of this virus,” said <b>Kathrin U. Jansen, Ph.D., Senior Vice President and Head of Vaccine Research &amp; Development, Pfizer</b>. “We thank the committee for their thoughtful review of the data and will work with the FDA following today’s meeting to address the committee’s questions, as we continue to believe in the benefits of a booster dose for a broader population.”</p>\n<p>“We are committed to support the ongoing efforts to reduce infections and COVID-19 cases. The data we submitted to the FDA, EMA and other regulatory authorities underline that a booster induces a strong immune response against all tested variants of concern and may contribute to address a public health need,” said <b>Özlem Türeci, M.D., Co-founder and Chief Medical Officer of BioNTech.</b></p>\n<p>VRBPAC based its recommendation on the totality of scientific evidence shared by the companies, including data from their clinical program evaluating the safety, tolerability and immunogenicity of a booster dose of COMIRNATY. A booster dose of the vaccine elicited significantly higher neutralizing antibody titers against the initial SARS-CoV-2 virus (wild type), as well as the Beta and Delta variants, when compared with the levels observed after the two-dose primary series. The reactogenicity profile within seven days after the booster dose was typically mild to moderate, and the frequency of reactions was similar to or lower than after dose two. The adverse event profile was generally consistent with other clinical safety data for COMIRNATY.</p>\n<p>Real-world surveillance data also were presented to the VRBPAC by the Israel Ministry of Health, providing further support for the public health impact of boosters. The data presented from Israel included an analysis published this week in <i>The New England Journal of Medicine</i>. The analysis comprised approximately 1.1 million individuals ages 60 years and older who were eligible for a booster dose of the vaccine between July 30 through August 31, 2021. No new safety signals were observed, and reported adverse events were lower than those observed after dose two. The analysis showed that a booster dose restored very high levels of protection against COVID-19 infections and severe disease in this period when Delta was the dominant strain. Individuals who received the booster dose were less likely by a factor of 11.3 (95% CI: 10.4, 12.3) to develop a confirmed infection and less likely by a factor of 19.5 (95% CI: 12.9, 29.5) to develop severe illness compared to those who were previously fully vaccinated but did not receive a booster dose. The additional protection after receiving a booster translated to vaccine effectiveness comparable to levels seen early in the country’s vaccine rollout (an estimated 95%), when the Alpha variant was predominant.</p>\n<p>Under the EUA of the Pfizer-BioNTech vaccine in the U.S., a third dose was <u>previously authorized</u> for individuals at least 12 years of age who have undergone solid organ transplant, or who are diagnosed with conditions that are considered to have an equivalent level of immunocompromise. This authorization of a third dose for immunocompromised individuals is separate and distinct from the booster dose reviewed by VRBPAC today. The third dose for immunocompromised individuals is meant to address the fact that these individuals sometimes do not build enough protection after two doses of the vaccine. In contrast, the booster dose recommended today by VRBPAC for EUA refers to an additional dose of the vaccine that is given to those who have built enough protection after the primary two-dose vaccination series, but may have decreased protection over time due to waning of immunity.</p>\n<p>COMIRNATY, which is based on BioNTech’s proprietary mRNA technology, was developed by both BioNTech and Pfizer. BioNTech is the Marketing Authorization Holder in the United States, the European Union, the United Kingdom, Canada and the holder of emergency use authorizations or equivalents in the United States (jointly with Pfizer) and other countries. Submissions to pursue regulatory approvals in those countries where emergency use authorizations or equivalent were initially granted are planned.</p>\n<p><b>U.S. Indication &amp; Authorized Use</b>COMIRNATY® (COVID-19 Vaccine, mRNA) is an FDA-approved COVID-19 vaccine made by Pfizer for BioNTech.</p>\n<ul>\n <li>It is approved as a 2-dose series for prevention of COVID-19 in individuals 16 years of age and older</li>\n <li>It is also authorized under Emergency Use Authorization (EUA) to be administered for emergency use to:</li>\n</ul>\n<p>The Pfizer-BioNTech COVID-19 Vaccine has received EUA from FDA to:</p>\n<ul>\n <li>prevent COVID-19 in individuals 12 years of age and older, and</li>\n <li>provide a third dose to individuals 12 years of age and older who have been determined to have certain kinds of immunocompromise</li>\n</ul>\n<p>The FDA-approved COMIRNATY® (COVID-19 Vaccine, mRNA) and the EUA-authorized Pfizer-BioNTech COVID-19 Vaccine have the same formulation and can be used interchangeably to provide the COVID-19 vaccination series. An individual may be offered either COMIRNATY® (COVID-19 Vaccine, mRNA) or the Pfizer-BioNTech COVID-19 Vaccine to prevent coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2.</p>\n<p><b>EUA Statement</b>This emergency use of the product has not been approved or licensed by FDA, but has been authorized by FDA under an Emergency Use Authorization (EUA) to prevent Coronavirus Disease 2019 (COVID-19) for use in individuals 12 years of age and older; and the emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product under Section 564(b)(1) of the FD&amp;C Act unless the declaration is terminated or authorization revoked sooner.</p>\n<p><b>Important Safety Information</b>Individuals should <b>not</b> get the Pfizer-BioNTech COVID-19 Vaccine if they:</p>\n<ul>\n <li>had a severe allergic reaction after a previous dose of this vaccine</li>\n <li>had a severe allergic reaction to any ingredient of this vaccine</li>\n</ul>\n<p>Individuals should tell the vaccination provider about all of their medical conditions, including if they:</p>\n<ul>\n <li>have any allergies</li>\n <li>have had myocarditis (inflammation of the heart muscle) or pericarditis (inflammation of the lining outside the heart)</li>\n <li>have a fever</li>\n <li>have a bleeding disorder or are on a blood thinner</li>\n <li>are immunocompromised or are on a medicine that affects the immune system</li>\n <li>are pregnant, plan to become pregnant, or are breastfeeding</li>\n <li>have received another COVID-19 vaccine</li>\n <li>have ever fainted in association with an injection</li>\n</ul>\n<p>The vaccine may not protect everyone.</p>\n<p>Side effects reported with the vaccine include:</p>\n<ul>\n <li>There is a remote chance that the vaccine could cause a severe allergic reaction</li>\n <li>Myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the lining outside the heart) have occurred in some people who have received the vaccine. In most of these people, symptoms began within a few days following receipt of the second dose of the vaccine. The chance of having this occur is very low. Individuals should seek medical attention right away if they have any of the following symptoms after receiving the vaccine:</li>\n <li>Side effects that have been reported with the vaccine include:</li>\n <li>These may not be all the possible side effects of the vaccine. Serious and unexpected side effects may occur. The vaccine is still being studied in clinical trials. Call the vaccination provider or healthcare provider about bothersome side effects or side effects that do not go away</li>\n</ul>\n<p>There is no information on the use of the vaccine with other vaccines.</p>\n<p>Patients should always ask their healthcare providers for medical advice about adverse events. Individuals are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit <u>http://www.vaers.hhs.gov</u> or call 1-800-822-7967. In addition, side effects can be reported to Pfizer Inc. at <u>www.pfizersafetyreporting.com</u> or by calling 1-800-438-1985.</p>\n<p>Please <u>click here</u> for full Prescribing Information (16+ years of age). Please <u>click here</u> for Fact Sheet for Vaccination Providers (12+ years of age).</p>\n<p><b>About Pfizer: Breakthroughs That Change Patients’ Lives</b>At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 170 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at <u>www.Pfizer.com</u>. In addition, to learn more, please visit us on <u>www.Pfizer.com</u> and follow us on <a href=\"https://laohu8.com/S/TWTR\">Twitter</a> at <u>@Pfizer</u> and <u>@Pfizer News</u>, <u>LinkedIn</u>, <u>YouTube</u> and like us on <a href=\"https://laohu8.com/S/FB\">Facebook</a> at <u>Facebook.com/Pfizer</u>.</p>\n<p><b>Pfizer Disclosure Notice</b>The information contained in this release is as of September 17, 2021. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.</p>\n<p>This release contains forward-looking information about Pfizer’s efforts to combat COVID-19, the collaboration between BioNTech and Pfizer to develop a COVID-19 vaccine, the BNT162 mRNA vaccine program and COMIRNATY (COVID-19 Vaccine, mRNA) (BNT162b2) (including a potential booster (third) dose and a supplemental Biologics License Application (sBLA) for a potential booster (third) dose of BNT162b2 in individuals 16 years of age and older in the U.S., qualitative assessments of available data, potential benefits, expectations for clinical trials, the anticipated timing of regulatory submissions, regulatory approvals or authorizations and anticipated manufacturing, distribution and supply) involving substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as risks associated with preclinical and clinical data (including the Phase 3 data), including the possibility of unfavorable new preclinical, clinical or safety data and further analyses of existing preclinical, clinical or safety data; whether and when our Phase 3 clinical trial will demonstrate protection from infection or disease following a booster (third) dose, which is the subject of ongoing study; the ability to produce comparable clinical or other results, including the rate of vaccine effectiveness and safety and tolerability profile observed to date, in additional analyses of the Phase 3 trial and additional studies or in larger, more diverse populations following commercialization; the ability of BNT162b2 to prevent COVID-19 caused by emerging virus variants; the risk that more widespread use of the vaccine will lead to new information about efficacy, safety, or other developments, including the risk of additional adverse reactions, some of which may be serious; the risk that preclinical and clinical trial data are subject to differing interpretations and assessments, including during the peer review/publication process, in the scientific community generally, and by regulatory authorities; whether and when additional data from the BNT162 mRNA vaccine program will be published in scientific journal publications and, if so, when and with what modifications and interpretations; whether regulatory authorities will be satisfied with the design of and results from these and any future preclinical and clinical studies; whether and when applications for a potential booster (third) dose will be filed in any other jurisdictions and whether and when other biologics license and/or emergency use authorization applications or amendments to any such applications may be filed in particular jurisdictions for BNT162b2 or any other potential vaccines that may arise from the BNT162 program, and if obtained, whether or when such emergency use authorization or licenses will expire or terminate; whether and when any applications that may be pending or filed for BNT162b2 (including the sBLA for a potential booster (third) dose in the U.S., applications that may be pending or filed for a potential booster (third) dose in other jurisdictions or any requested amendments to the emergency use or conditional marketing authorizations) or other vaccines that may result from the BNT162 program may be approved by particular regulatory authorities, which will depend on myriad factors, including making a determination as to whether the vaccine’s benefits outweigh its known risks and determination of the vaccine’s efficacy and, if approved, whether it will be commercially successful; decisions by regulatory authorities impacting labeling or marketing, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of a vaccine, including development of products or therapies by other companies; disruptions in the relationships between us and our collaboration partners, clinical trial sites or third-party suppliers; the risk that demand for any products may be reduced or no longer exist; risks related to the availability of raw materials to manufacture a vaccine; challenges related to our vaccine’s ultra-low temperature formulation, two-dose schedule and attendant storage, distribution and administration requirements, including risks related to storage and handling after delivery by Pfizer; the risk that we may not be able to successfully develop other vaccine formulations, booster doses or new variant-specific vaccines; the risk that we may not be able to create or scale up manufacturing capacity on a timely basis or maintain access to logistics or supply channels commensurate with global demand for our vaccine, which would negatively impact our ability to supply the estimated numbers of doses of our vaccine within the projected time periods as previously indicated; whether and when additional supply agreements will be reached; uncertainties regarding the ability to obtain recommendations from vaccine advisory or technical committees and other public health authorities and uncertainties regarding the commercial impact of any such recommendations; challenges related to public vaccine confidence or awareness; uncertainties regarding the impact of COVID-19 on Pfizer’s business, operations and financial results; and competitive developments.</p>\n<p>A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results”, as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at <u>www.sec.gov</u> and <u>www.pfizer.com</u>.</p>\n<p><b>About BioNTech</b>Biopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, <a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a>, Bayer Animal Health, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer. For more information, please visit <u>www.BioNTech.de</u>.</p>\n<p><b>BioNTech Forward-looking Statements</b>This press release contains “forward-looking statements” of BioNTech within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include, but may not be limited to, statements concerning: BioNTech’s efforts to combat COVID-19; the collaboration between BioNTech and Pfizer including the program to develop a COVID-19 vaccine and COMIRNATY (COVID-19 Vaccine, mRNA) (BNT162b2) (including a potential booster (third) dose of BNT162b2 in individuals 16 years of age and older in the U.S., a definite submission of a supplemental BLA for a potential booster dose of a variation of BNT162b2 having a modified mRNA sequence in the U.S., a BLA to support potential full FDA approval of BNT162b2 in individuals 12 through 15 years, whether and when applications for a potential booster (third) dose will be filed in any other jurisdictions, qualitative assessments of available data, potential benefits, expectations for clinical trials, the anticipated timing of regulatory submissions, regulatory approvals or authorizations and anticipated manufacturing, distribution and supply); our expectations regarding the potential characteristics of BNT162b2 in our clinical trials and/or in commercial use based on data observations to date; the ability of BNT162b2 to prevent COVID-19 caused by emerging virus variants; the expected time point for additional readouts on efficacy data of BNT162b2 in our clinical trials; the nature of the clinical data, which is subject to ongoing peer review, regulatory review and market interpretation; the timing for submission of data for, or receipt of, any marketing approval or Emergency Use Authorization; our contemplated shipping and storage plan, including our estimated product shelf life at various temperatures; and the ability of BioNTech to supply the quantities of BNT162 to support clinical development and market demand, including our production estimates for 2021. Any forward-looking statements in this press release are based on BioNTech current expectations and beliefs of future events, and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the ability to meet the pre-defined endpoints in clinical trials; competition to create a vaccine for COVID-19; the ability to produce comparable clinical or other results, including our stated rate of vaccine effectiveness and safety and tolerability profile observed to date, in the remainder of the trial or in larger, more diverse populations upon commercialization; the ability to effectively scale our productions capabilities; and other potential difficulties.</p>\n<p>For a discussion of these and other risks and uncertainties, see BioNTech’s Annual Report as Form 20-F for the Year Ended December 31, 2020, filed with the SEC on March 30, 2021, which is available on the SEC’s website at <u>www.sec.gov</u>. All information in this press release is as of the date of the release, and BioNTech undertakes no duty to update this information unless required by law.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>FDA Advisory Committee Votes Unanimously in Favor of COMIRNATY® Booster for Emergency Use in People 65 and Older and Certain High-Risk Populations</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFDA Advisory Committee Votes Unanimously in Favor of COMIRNATY® Booster for Emergency Use in People 65 and Older and Certain High-Risk Populations\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-18 15:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=18955632><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Committee reviewed clinical data showing a booster dose of COMIRNATY® elicits high neutralization titers against SARS-CoV-2 and all currently tested variants \nReactogenicity profile within seven days ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=18955632\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://www.streetinsider.com/dr/news.php?id=18955632","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2168957763","content_text":"Committee reviewed clinical data showing a booster dose of COMIRNATY® elicits high neutralization titers against SARS-CoV-2 and all currently tested variants \nReactogenicity profile within seven days of the booster dose was typically mild to moderate, with frequency of reactions similar to or lower than after the primary vaccination series\nReal-world data presented by Israel Ministry of Health show additional protection after receiving a booster translated to vaccine effectiveness comparable to levels seen early in the country’s vaccine rollout\nFDA expected to make its decision in the coming days \n\nNEW YORK AND MAINZ, GERMANY, September 17, 2021—Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced today that the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted unanimously to recommend the FDA grant Emergency Use Authorization (EUA) for a booster dose of COMIRNATY® (COVID-19 Vaccine, mRNA) in individuals 65 years of age and older and individuals at high risk of severe COVID-19. The committee recommended that the additional dose be administered at least six months after the two-dose series. The panel also agreed that healthcare workers and others at high risk for occupational exposure should be included in this EUA.\nVRBPAC is made up of independent experts who advise the FDA on scientific and regulatory matters, including the evaluation of vaccine safety and efficacy.\nAt this time, VRBPAC did not vote in favor of approval of a booster dose for the full population for which Pfizer and BioNTech submitted their supplemental Biologics License Application, which was individuals 16 and older. The same data have recently been submitted to the European Medicines Agency (EMA) and will be filed with other regulatory authorities in the coming weeks. The companies remain vigilant and continue to generate relevant COMIRNATY booster dose data for evaluation for future licensure in further groups as well as to address emerging variants of concern.\nThe FDA is expected to make its decision in the coming days. This decision could allow COMIRNATY to be the first COVID-19 vaccine with a booster authorized in the U.S.\n“Today the VRBPAC reviewed data from our clinical program showing a favorable safety profile and strong immune responses against SARS-CoV-2 after a booster dose of our vaccine. These data, and the larger body of scientific evidence presented at the meeting, underscore our belief that boosters can be a critical tool in the ongoing effort to control the spread of this virus,” said Kathrin U. Jansen, Ph.D., Senior Vice President and Head of Vaccine Research & Development, Pfizer. “We thank the committee for their thoughtful review of the data and will work with the FDA following today’s meeting to address the committee’s questions, as we continue to believe in the benefits of a booster dose for a broader population.”\n“We are committed to support the ongoing efforts to reduce infections and COVID-19 cases. The data we submitted to the FDA, EMA and other regulatory authorities underline that a booster induces a strong immune response against all tested variants of concern and may contribute to address a public health need,” said Özlem Türeci, M.D., Co-founder and Chief Medical Officer of BioNTech.\nVRBPAC based its recommendation on the totality of scientific evidence shared by the companies, including data from their clinical program evaluating the safety, tolerability and immunogenicity of a booster dose of COMIRNATY. A booster dose of the vaccine elicited significantly higher neutralizing antibody titers against the initial SARS-CoV-2 virus (wild type), as well as the Beta and Delta variants, when compared with the levels observed after the two-dose primary series. The reactogenicity profile within seven days after the booster dose was typically mild to moderate, and the frequency of reactions was similar to or lower than after dose two. The adverse event profile was generally consistent with other clinical safety data for COMIRNATY.\nReal-world surveillance data also were presented to the VRBPAC by the Israel Ministry of Health, providing further support for the public health impact of boosters. The data presented from Israel included an analysis published this week in The New England Journal of Medicine. The analysis comprised approximately 1.1 million individuals ages 60 years and older who were eligible for a booster dose of the vaccine between July 30 through August 31, 2021. No new safety signals were observed, and reported adverse events were lower than those observed after dose two. The analysis showed that a booster dose restored very high levels of protection against COVID-19 infections and severe disease in this period when Delta was the dominant strain. Individuals who received the booster dose were less likely by a factor of 11.3 (95% CI: 10.4, 12.3) to develop a confirmed infection and less likely by a factor of 19.5 (95% CI: 12.9, 29.5) to develop severe illness compared to those who were previously fully vaccinated but did not receive a booster dose. The additional protection after receiving a booster translated to vaccine effectiveness comparable to levels seen early in the country’s vaccine rollout (an estimated 95%), when the Alpha variant was predominant.\nUnder the EUA of the Pfizer-BioNTech vaccine in the U.S., a third dose was previously authorized for individuals at least 12 years of age who have undergone solid organ transplant, or who are diagnosed with conditions that are considered to have an equivalent level of immunocompromise. This authorization of a third dose for immunocompromised individuals is separate and distinct from the booster dose reviewed by VRBPAC today. The third dose for immunocompromised individuals is meant to address the fact that these individuals sometimes do not build enough protection after two doses of the vaccine. In contrast, the booster dose recommended today by VRBPAC for EUA refers to an additional dose of the vaccine that is given to those who have built enough protection after the primary two-dose vaccination series, but may have decreased protection over time due to waning of immunity.\nCOMIRNATY, which is based on BioNTech’s proprietary mRNA technology, was developed by both BioNTech and Pfizer. BioNTech is the Marketing Authorization Holder in the United States, the European Union, the United Kingdom, Canada and the holder of emergency use authorizations or equivalents in the United States (jointly with Pfizer) and other countries. Submissions to pursue regulatory approvals in those countries where emergency use authorizations or equivalent were initially granted are planned.\nU.S. Indication & Authorized UseCOMIRNATY® (COVID-19 Vaccine, mRNA) is an FDA-approved COVID-19 vaccine made by Pfizer for BioNTech.\n\nIt is approved as a 2-dose series for prevention of COVID-19 in individuals 16 years of age and older\nIt is also authorized under Emergency Use Authorization (EUA) to be administered for emergency use to:\n\nThe Pfizer-BioNTech COVID-19 Vaccine has received EUA from FDA to:\n\nprevent COVID-19 in individuals 12 years of age and older, and\nprovide a third dose to individuals 12 years of age and older who have been determined to have certain kinds of immunocompromise\n\nThe FDA-approved COMIRNATY® (COVID-19 Vaccine, mRNA) and the EUA-authorized Pfizer-BioNTech COVID-19 Vaccine have the same formulation and can be used interchangeably to provide the COVID-19 vaccination series. An individual may be offered either COMIRNATY® (COVID-19 Vaccine, mRNA) or the Pfizer-BioNTech COVID-19 Vaccine to prevent coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2.\nEUA StatementThis emergency use of the product has not been approved or licensed by FDA, but has been authorized by FDA under an Emergency Use Authorization (EUA) to prevent Coronavirus Disease 2019 (COVID-19) for use in individuals 12 years of age and older; and the emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product under Section 564(b)(1) of the FD&C Act unless the declaration is terminated or authorization revoked sooner.\nImportant Safety InformationIndividuals should not get the Pfizer-BioNTech COVID-19 Vaccine if they:\n\nhad a severe allergic reaction after a previous dose of this vaccine\nhad a severe allergic reaction to any ingredient of this vaccine\n\nIndividuals should tell the vaccination provider about all of their medical conditions, including if they:\n\nhave any allergies\nhave had myocarditis (inflammation of the heart muscle) or pericarditis (inflammation of the lining outside the heart)\nhave a fever\nhave a bleeding disorder or are on a blood thinner\nare immunocompromised or are on a medicine that affects the immune system\nare pregnant, plan to become pregnant, or are breastfeeding\nhave received another COVID-19 vaccine\nhave ever fainted in association with an injection\n\nThe vaccine may not protect everyone.\nSide effects reported with the vaccine include:\n\nThere is a remote chance that the vaccine could cause a severe allergic reaction\nMyocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the lining outside the heart) have occurred in some people who have received the vaccine. In most of these people, symptoms began within a few days following receipt of the second dose of the vaccine. The chance of having this occur is very low. Individuals should seek medical attention right away if they have any of the following symptoms after receiving the vaccine:\nSide effects that have been reported with the vaccine include:\nThese may not be all the possible side effects of the vaccine. Serious and unexpected side effects may occur. The vaccine is still being studied in clinical trials. Call the vaccination provider or healthcare provider about bothersome side effects or side effects that do not go away\n\nThere is no information on the use of the vaccine with other vaccines.\nPatients should always ask their healthcare providers for medical advice about adverse events. Individuals are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit http://www.vaers.hhs.gov or call 1-800-822-7967. In addition, side effects can be reported to Pfizer Inc. at www.pfizersafetyreporting.com or by calling 1-800-438-1985.\nPlease click here for full Prescribing Information (16+ years of age). Please click here for Fact Sheet for Vaccination Providers (12+ years of age).\nAbout Pfizer: Breakthroughs That Change Patients’ LivesAt Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 170 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.Pfizer.com. In addition, to learn more, please visit us on www.Pfizer.com and follow us on Twitter at @Pfizer and @Pfizer News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer.\nPfizer Disclosure NoticeThe information contained in this release is as of September 17, 2021. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.\nThis release contains forward-looking information about Pfizer’s efforts to combat COVID-19, the collaboration between BioNTech and Pfizer to develop a COVID-19 vaccine, the BNT162 mRNA vaccine program and COMIRNATY (COVID-19 Vaccine, mRNA) (BNT162b2) (including a potential booster (third) dose and a supplemental Biologics License Application (sBLA) for a potential booster (third) dose of BNT162b2 in individuals 16 years of age and older in the U.S., qualitative assessments of available data, potential benefits, expectations for clinical trials, the anticipated timing of regulatory submissions, regulatory approvals or authorizations and anticipated manufacturing, distribution and supply) involving substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as risks associated with preclinical and clinical data (including the Phase 3 data), including the possibility of unfavorable new preclinical, clinical or safety data and further analyses of existing preclinical, clinical or safety data; whether and when our Phase 3 clinical trial will demonstrate protection from infection or disease following a booster (third) dose, which is the subject of ongoing study; the ability to produce comparable clinical or other results, including the rate of vaccine effectiveness and safety and tolerability profile observed to date, in additional analyses of the Phase 3 trial and additional studies or in larger, more diverse populations following commercialization; the ability of BNT162b2 to prevent COVID-19 caused by emerging virus variants; the risk that more widespread use of the vaccine will lead to new information about efficacy, safety, or other developments, including the risk of additional adverse reactions, some of which may be serious; the risk that preclinical and clinical trial data are subject to differing interpretations and assessments, including during the peer review/publication process, in the scientific community generally, and by regulatory authorities; whether and when additional data from the BNT162 mRNA vaccine program will be published in scientific journal publications and, if so, when and with what modifications and interpretations; whether regulatory authorities will be satisfied with the design of and results from these and any future preclinical and clinical studies; whether and when applications for a potential booster (third) dose will be filed in any other jurisdictions and whether and when other biologics license and/or emergency use authorization applications or amendments to any such applications may be filed in particular jurisdictions for BNT162b2 or any other potential vaccines that may arise from the BNT162 program, and if obtained, whether or when such emergency use authorization or licenses will expire or terminate; whether and when any applications that may be pending or filed for BNT162b2 (including the sBLA for a potential booster (third) dose in the U.S., applications that may be pending or filed for a potential booster (third) dose in other jurisdictions or any requested amendments to the emergency use or conditional marketing authorizations) or other vaccines that may result from the BNT162 program may be approved by particular regulatory authorities, which will depend on myriad factors, including making a determination as to whether the vaccine’s benefits outweigh its known risks and determination of the vaccine’s efficacy and, if approved, whether it will be commercially successful; decisions by regulatory authorities impacting labeling or marketing, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of a vaccine, including development of products or therapies by other companies; disruptions in the relationships between us and our collaboration partners, clinical trial sites or third-party suppliers; the risk that demand for any products may be reduced or no longer exist; risks related to the availability of raw materials to manufacture a vaccine; challenges related to our vaccine’s ultra-low temperature formulation, two-dose schedule and attendant storage, distribution and administration requirements, including risks related to storage and handling after delivery by Pfizer; the risk that we may not be able to successfully develop other vaccine formulations, booster doses or new variant-specific vaccines; the risk that we may not be able to create or scale up manufacturing capacity on a timely basis or maintain access to logistics or supply channels commensurate with global demand for our vaccine, which would negatively impact our ability to supply the estimated numbers of doses of our vaccine within the projected time periods as previously indicated; whether and when additional supply agreements will be reached; uncertainties regarding the ability to obtain recommendations from vaccine advisory or technical committees and other public health authorities and uncertainties regarding the commercial impact of any such recommendations; challenges related to public vaccine confidence or awareness; uncertainties regarding the impact of COVID-19 on Pfizer’s business, operations and financial results; and competitive developments.\nA further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results”, as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com.\nAbout BioNTechBiopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer. For more information, please visit www.BioNTech.de.\nBioNTech Forward-looking StatementsThis press release contains “forward-looking statements” of BioNTech within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include, but may not be limited to, statements concerning: BioNTech’s efforts to combat COVID-19; the collaboration between BioNTech and Pfizer including the program to develop a COVID-19 vaccine and COMIRNATY (COVID-19 Vaccine, mRNA) (BNT162b2) (including a potential booster (third) dose of BNT162b2 in individuals 16 years of age and older in the U.S., a definite submission of a supplemental BLA for a potential booster dose of a variation of BNT162b2 having a modified mRNA sequence in the U.S., a BLA to support potential full FDA approval of BNT162b2 in individuals 12 through 15 years, whether and when applications for a potential booster (third) dose will be filed in any other jurisdictions, qualitative assessments of available data, potential benefits, expectations for clinical trials, the anticipated timing of regulatory submissions, regulatory approvals or authorizations and anticipated manufacturing, distribution and supply); our expectations regarding the potential characteristics of BNT162b2 in our clinical trials and/or in commercial use based on data observations to date; the ability of BNT162b2 to prevent COVID-19 caused by emerging virus variants; the expected time point for additional readouts on efficacy data of BNT162b2 in our clinical trials; the nature of the clinical data, which is subject to ongoing peer review, regulatory review and market interpretation; the timing for submission of data for, or receipt of, any marketing approval or Emergency Use Authorization; our contemplated shipping and storage plan, including our estimated product shelf life at various temperatures; and the ability of BioNTech to supply the quantities of BNT162 to support clinical development and market demand, including our production estimates for 2021. Any forward-looking statements in this press release are based on BioNTech current expectations and beliefs of future events, and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the ability to meet the pre-defined endpoints in clinical trials; competition to create a vaccine for COVID-19; the ability to produce comparable clinical or other results, including our stated rate of vaccine effectiveness and safety and tolerability profile observed to date, in the remainder of the trial or in larger, more diverse populations upon commercialization; the ability to effectively scale our productions capabilities; and other potential difficulties.\nFor a discussion of these and other risks and uncertainties, see BioNTech’s Annual Report as Form 20-F for the Year Ended December 31, 2020, filed with the SEC on March 30, 2021, which is available on the SEC’s website at www.sec.gov. All information in this press release is as of the date of the release, and BioNTech undertakes no duty to update this information unless required by law.","news_type":1},"isVote":1,"tweetType":1,"viewCount":68,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":882372145,"gmtCreate":1631664510387,"gmtModify":1676530602354,"author":{"id":"4088497713200830","authorId":"4088497713200830","name":"skxrena","avatar":"https://static.tigerbbs.com/bcd0597b7a18627a33a524d8ac6dd51d","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4088497713200830","idStr":"4088497713200830"},"themes":[],"htmlText":"go go go","listText":"go go go","text":"go go go","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/882372145","repostId":"2167568176","repostType":4,"repost":{"id":"2167568176","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1631662384,"share":"https://ttm.financial/m/news/2167568176?lang=&edition=fundamental","pubTime":"2021-09-15 07:33","market":"us","language":"en","title":"Apple's new iPhone 13 touts faster 5G, sharper cameras to spur trade-ins","url":"https://stock-news.laohu8.com/highlight/detail?id=2167568176","media":"Reuters","summary":"Sept 14 (Reuters) - Apple Inc unveiled the iPhone 13 and a new iPad mini on Tuesday, expanding 5G co","content":"<p>Sept 14 (Reuters) - Apple Inc unveiled the iPhone 13 and a new iPad mini on Tuesday, expanding 5G connectivity and showing off faster chips and sharper cameras without raising the phone's price.</p>\n<p>The Cupertino, California-based company did not announce any blockbuster features or products, but analysts expect customers hanging onto older models like the iPhone X will be eager to upgrade. To encourage trade-ins, participating wireless carriers are offering incentives ahead of the year-end holiday season that to make the new phones free to some customers.</p>\n<p>The iPhone 13&nbsp;will have a new chip called the A15 Bionic that enables features like automatically translating text. The phone also has a better display, longer battery life and a Cinematic mode for automatically changing focus while taking videos. Apple said the iPhone 13 will have custom 5G antennas and radio components for faster speeds and will come in five colors.</p>\n<p>The phone will start at $699, and participating wireless carriers will offer up to $700 off for qualifying trade-ins. The iPhone 13 Pro starts at $999 and the Pro Max starts at $1,099, with trade-in offers of up to $1,000. All three models will be available Sept. 24.</p>\n<p>The prices are unchanged from last year, but some carriers such as AT&amp;T Inc will offer the devices for no additional charge with subsidies of up to $1,000 if customers trade in a previous model and sign up for an installment plan.</p>\n<p>Verizon Communications Inc&nbsp;and <a href=\"https://laohu8.com/S/TMUSR\">T-Mobile US Inc</a>&nbsp;offered similar deals but with slightly lower subsidies up to $700. The biggest subsidies will go to customers who turn in iPhone 11 and iPhone 12 models.</p>\n<p>Ben Bajarin, head of consumer technologies at Creative Strategies, said he expects those aggressive subsides will increase as Apple and carriers try to hold onto customers.</p>\n<p>\"That offer is unique to Apple, and it's a strength they have to keep these sales cycles going for them and for the carriers,\" Bajarin said.</p>\n<p>The iPhone is Apple's most important product, but Apple has rolled out a web of service and other products that are seen as locking customers into a system they enjoy -- and would find expensive to leave.</p>\n<p>The Series 7 smart watch will feature a larger display and faster charging. It will start at $399 and be available later this autumn.</p>\n<p>The company also updated its iPad Mini with 5G connectivity and a reworked design that makes it look like the higher-end iPad Air and Pro models. Bob O'Donnell, head of TECHnalysis Research, said the small tablet was Apple's most surprising announcement and could lure in customers who want a device with 5G that can handle more powerful apps than a phone.</p>\n<p>\"I don't think it replaces any other device, like we've seen Apple try to position some of the bigger iPads as PC replacements,\" O'Donnell said.</p>\n<p>The new iPad Mini's price rose by $100, but it also added new capabilities like compatibility with the company's Apple Pencil and a faster chip than the larger-screened base model iPad, bucking a trend of smaller screens being cheaper. Apple showed the Mini in use by professionals like doctors.</p>\n<p>Apple also updated its base-model iPad with a new camera. The new iPad will start at $329 and the Mini at $499. Both will be available next week.</p>\n<p>Apple shares closed down about 1%, a sharper fall than a slight downturn in broader markets.</p>\n<p>\"It seems like there's nothing really revolutionary announced, but of course, as usual, they announced enough improvements to at least generate some enthusiasm among consumers,\" said Rick Meckler, partner at family investment office Cherry Lane Investments.</p>\n<p>Apple's biggest product launch of the year comes as some of the shine has come off its stock as business practices such as charging software developers commissions on in-app payments have come under regulatory scrutiny.</p>\n<p>Apple shares were up about 11.6% year to date as of Tuesday's close, trailing the Nasdaq Composite Index , which was up 16.7% over the same period.</p>\n<p>Kim Forrest, founder and chief investment officer at Bokeh Capital, said she was not concerned by the lack of splashy, unexpected products, since Apple's upgrades would keep customers. \"I think the consumer, once it gets the Apple chip in its head, it's very hard to dislodge,\" she said.</p>\n<p>The Apple Watch has become a cornerstone of its $30.6 billion accessories segment, which was up 25% in Apple's most recent fiscal year even as its iPhone revenue declined slightly. Analysts widely believe that Apple users who buy more than <a href=\"https://laohu8.com/S/AONE.U\">one</a> product - such as an Apple Watch and iPhone - are more likely to stick with the brand and spend on the company's apps and services.</p>\n<p>Apple focused on fitness features such as improving how the watch tracks bicycling workouts and dust protection for hiking. The watch is paired tightly with Apple Fitness+, a paid service offering guided workouts with Apple instructors. The company added pilates, skiing-oriented workouts and group workouts.</p>\n<p>Shares of exercise bike and online training company Peloton&nbsp;were down about 1.6%.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Apple's new iPhone 13 touts faster 5G, sharper cameras to spur trade-ins</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nApple's new iPhone 13 touts faster 5G, sharper cameras to spur trade-ins\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-09-15 07:33</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Sept 14 (Reuters) - Apple Inc unveiled the iPhone 13 and a new iPad mini on Tuesday, expanding 5G connectivity and showing off faster chips and sharper cameras without raising the phone's price.</p>\n<p>The Cupertino, California-based company did not announce any blockbuster features or products, but analysts expect customers hanging onto older models like the iPhone X will be eager to upgrade. To encourage trade-ins, participating wireless carriers are offering incentives ahead of the year-end holiday season that to make the new phones free to some customers.</p>\n<p>The iPhone 13&nbsp;will have a new chip called the A15 Bionic that enables features like automatically translating text. The phone also has a better display, longer battery life and a Cinematic mode for automatically changing focus while taking videos. Apple said the iPhone 13 will have custom 5G antennas and radio components for faster speeds and will come in five colors.</p>\n<p>The phone will start at $699, and participating wireless carriers will offer up to $700 off for qualifying trade-ins. The iPhone 13 Pro starts at $999 and the Pro Max starts at $1,099, with trade-in offers of up to $1,000. All three models will be available Sept. 24.</p>\n<p>The prices are unchanged from last year, but some carriers such as AT&amp;T Inc will offer the devices for no additional charge with subsidies of up to $1,000 if customers trade in a previous model and sign up for an installment plan.</p>\n<p>Verizon Communications Inc&nbsp;and <a href=\"https://laohu8.com/S/TMUSR\">T-Mobile US Inc</a>&nbsp;offered similar deals but with slightly lower subsidies up to $700. The biggest subsidies will go to customers who turn in iPhone 11 and iPhone 12 models.</p>\n<p>Ben Bajarin, head of consumer technologies at Creative Strategies, said he expects those aggressive subsides will increase as Apple and carriers try to hold onto customers.</p>\n<p>\"That offer is unique to Apple, and it's a strength they have to keep these sales cycles going for them and for the carriers,\" Bajarin said.</p>\n<p>The iPhone is Apple's most important product, but Apple has rolled out a web of service and other products that are seen as locking customers into a system they enjoy -- and would find expensive to leave.</p>\n<p>The Series 7 smart watch will feature a larger display and faster charging. It will start at $399 and be available later this autumn.</p>\n<p>The company also updated its iPad Mini with 5G connectivity and a reworked design that makes it look like the higher-end iPad Air and Pro models. Bob O'Donnell, head of TECHnalysis Research, said the small tablet was Apple's most surprising announcement and could lure in customers who want a device with 5G that can handle more powerful apps than a phone.</p>\n<p>\"I don't think it replaces any other device, like we've seen Apple try to position some of the bigger iPads as PC replacements,\" O'Donnell said.</p>\n<p>The new iPad Mini's price rose by $100, but it also added new capabilities like compatibility with the company's Apple Pencil and a faster chip than the larger-screened base model iPad, bucking a trend of smaller screens being cheaper. Apple showed the Mini in use by professionals like doctors.</p>\n<p>Apple also updated its base-model iPad with a new camera. The new iPad will start at $329 and the Mini at $499. Both will be available next week.</p>\n<p>Apple shares closed down about 1%, a sharper fall than a slight downturn in broader markets.</p>\n<p>\"It seems like there's nothing really revolutionary announced, but of course, as usual, they announced enough improvements to at least generate some enthusiasm among consumers,\" said Rick Meckler, partner at family investment office Cherry Lane Investments.</p>\n<p>Apple's biggest product launch of the year comes as some of the shine has come off its stock as business practices such as charging software developers commissions on in-app payments have come under regulatory scrutiny.</p>\n<p>Apple shares were up about 11.6% year to date as of Tuesday's close, trailing the Nasdaq Composite Index , which was up 16.7% over the same period.</p>\n<p>Kim Forrest, founder and chief investment officer at Bokeh Capital, said she was not concerned by the lack of splashy, unexpected products, since Apple's upgrades would keep customers. \"I think the consumer, once it gets the Apple chip in its head, it's very hard to dislodge,\" she said.</p>\n<p>The Apple Watch has become a cornerstone of its $30.6 billion accessories segment, which was up 25% in Apple's most recent fiscal year even as its iPhone revenue declined slightly. Analysts widely believe that Apple users who buy more than <a href=\"https://laohu8.com/S/AONE.U\">one</a> product - such as an Apple Watch and iPhone - are more likely to stick with the brand and spend on the company's apps and services.</p>\n<p>Apple focused on fitness features such as improving how the watch tracks bicycling workouts and dust protection for hiking. The watch is paired tightly with Apple Fitness+, a paid service offering guided workouts with Apple instructors. The company added pilates, skiing-oriented workouts and group workouts.</p>\n<p>Shares of exercise bike and online training company Peloton&nbsp;were down about 1.6%.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AAPL":"苹果","T":"美国电话电报","VZ":"威瑞森","TMUS":"T-Mobile US Inc"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2167568176","content_text":"Sept 14 (Reuters) - Apple Inc unveiled the iPhone 13 and a new iPad mini on Tuesday, expanding 5G connectivity and showing off faster chips and sharper cameras without raising the phone's price.\nThe Cupertino, California-based company did not announce any blockbuster features or products, but analysts expect customers hanging onto older models like the iPhone X will be eager to upgrade. To encourage trade-ins, participating wireless carriers are offering incentives ahead of the year-end holiday season that to make the new phones free to some customers.\nThe iPhone 13 will have a new chip called the A15 Bionic that enables features like automatically translating text. The phone also has a better display, longer battery life and a Cinematic mode for automatically changing focus while taking videos. Apple said the iPhone 13 will have custom 5G antennas and radio components for faster speeds and will come in five colors.\nThe phone will start at $699, and participating wireless carriers will offer up to $700 off for qualifying trade-ins. The iPhone 13 Pro starts at $999 and the Pro Max starts at $1,099, with trade-in offers of up to $1,000. All three models will be available Sept. 24.\nThe prices are unchanged from last year, but some carriers such as AT&T Inc will offer the devices for no additional charge with subsidies of up to $1,000 if customers trade in a previous model and sign up for an installment plan.\nVerizon Communications Inc and T-Mobile US Inc offered similar deals but with slightly lower subsidies up to $700. The biggest subsidies will go to customers who turn in iPhone 11 and iPhone 12 models.\nBen Bajarin, head of consumer technologies at Creative Strategies, said he expects those aggressive subsides will increase as Apple and carriers try to hold onto customers.\n\"That offer is unique to Apple, and it's a strength they have to keep these sales cycles going for them and for the carriers,\" Bajarin said.\nThe iPhone is Apple's most important product, but Apple has rolled out a web of service and other products that are seen as locking customers into a system they enjoy -- and would find expensive to leave.\nThe Series 7 smart watch will feature a larger display and faster charging. It will start at $399 and be available later this autumn.\nThe company also updated its iPad Mini with 5G connectivity and a reworked design that makes it look like the higher-end iPad Air and Pro models. Bob O'Donnell, head of TECHnalysis Research, said the small tablet was Apple's most surprising announcement and could lure in customers who want a device with 5G that can handle more powerful apps than a phone.\n\"I don't think it replaces any other device, like we've seen Apple try to position some of the bigger iPads as PC replacements,\" O'Donnell said.\nThe new iPad Mini's price rose by $100, but it also added new capabilities like compatibility with the company's Apple Pencil and a faster chip than the larger-screened base model iPad, bucking a trend of smaller screens being cheaper. Apple showed the Mini in use by professionals like doctors.\nApple also updated its base-model iPad with a new camera. The new iPad will start at $329 and the Mini at $499. Both will be available next week.\nApple shares closed down about 1%, a sharper fall than a slight downturn in broader markets.\n\"It seems like there's nothing really revolutionary announced, but of course, as usual, they announced enough improvements to at least generate some enthusiasm among consumers,\" said Rick Meckler, partner at family investment office Cherry Lane Investments.\nApple's biggest product launch of the year comes as some of the shine has come off its stock as business practices such as charging software developers commissions on in-app payments have come under regulatory scrutiny.\nApple shares were up about 11.6% year to date as of Tuesday's close, trailing the Nasdaq Composite Index , which was up 16.7% over the same period.\nKim Forrest, founder and chief investment officer at Bokeh Capital, said she was not concerned by the lack of splashy, unexpected products, since Apple's upgrades would keep customers. \"I think the consumer, once it gets the Apple chip in its head, it's very hard to dislodge,\" she said.\nThe Apple Watch has become a cornerstone of its $30.6 billion accessories segment, which was up 25% in Apple's most recent fiscal year even as its iPhone revenue declined slightly. Analysts widely believe that Apple users who buy more than one product - such as an Apple Watch and iPhone - are more likely to stick with the brand and spend on the company's apps and services.\nApple focused on fitness features such as improving how the watch tracks bicycling workouts and dust protection for hiking. The watch is paired tightly with Apple Fitness+, a paid service offering guided workouts with Apple instructors. The company added pilates, skiing-oriented workouts and group workouts.\nShares of exercise bike and online training company Peloton were down about 1.6%.","news_type":1},"isVote":1,"tweetType":1,"viewCount":408,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":818188354,"gmtCreate":1630384343578,"gmtModify":1676530287871,"author":{"id":"4088497713200830","authorId":"4088497713200830","name":"skxrena","avatar":"https://static.tigerbbs.com/bcd0597b7a18627a33a524d8ac6dd51d","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4088497713200830","idStr":"4088497713200830"},"themes":[],"htmlText":"up please!","listText":"up please!","text":"up please!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/818188354","repostId":"1104186500","repostType":4,"isVote":1,"tweetType":1,"viewCount":439,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":810166459,"gmtCreate":1629953230871,"gmtModify":1676530182952,"author":{"id":"4088497713200830","authorId":"4088497713200830","name":"skxrena","avatar":"https://static.tigerbbs.com/bcd0597b7a18627a33a524d8ac6dd51d","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4088497713200830","idStr":"4088497713200830"},"themes":[],"htmlText":"good","listText":"good","text":"good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/810166459","repostId":"1197778368","repostType":4,"repost":{"id":"1197778368","pubTimestamp":1629932731,"share":"https://ttm.financial/m/news/1197778368?lang=&edition=fundamental","pubTime":"2021-08-26 07:05","market":"us","language":"en","title":"S&P 500, Nasdaq notch all-time closing highs ahead of Jackson Hole","url":"https://stock-news.laohu8.com/highlight/detail?id=1197778368","media":"Reuters","summary":"NEW YORK (Reuters) - Wall Street gained ground again on Wednesday, with chipmakers and financials he","content":"<p>NEW YORK (Reuters) - Wall Street gained ground again on Wednesday, with chipmakers and financials helping to push the S&amp;P 500 and the Nasdaq to record closing highs as investors look to the upcoming Jackson Hole Symposium for assurances that Federal Reserve’s timeline for policy tightening remains intact.</p>\n<p>With few negative catalysts to sour the risk-on sentiment, all three major U.S. indexes ended the session modestly higher.</p>\n<p>“Positive news on vaccination approvals, and expectations that the Fed won’t shock markets at Jackson Hole, are helping to keep equity prices higher,” said David Carter, chief investment officer at Lenox Wealth Advisors in New York, who added “it’s a very quiet market as many investors are sitting on the beach this week.”</p>\n<p>Rising U.S. Treasury yields boosted rate sensitive financials, and sectors that stand to gain most from economic revival - smallcaps, chips and transports - were outperforming the broader market.</p>\n<p>Days after the Food and Drug Administration gave full approval to the Pfizer-BioNTech COVID-19 vaccine, companies and institutions are moving toward either mandated inoculation, or penalization for those who forego the shot.</p>\n<p>The Pentagon and Delta Air Lines are the latest to enact such measures, with Ford Motor Co and others potentially following suit.</p>\n<p>For an interactive graphic on global vaccine deployment and new infection rates, click here.</p>\n<p>The session marked the S&amp;P 500’s 51st record high close so far this year.</p>\n<p>Analysts polled by Reuters, however, see the stock market staying rangebound for the remainder of 2021, with the S&amp;P 500 ending the year little changed as the pandemic recovery, along with corporate earnings growth, lose steam.</p>\n<p>“Following a long run, equity indexes have cooled off as the next engine of growth is unclear,” Carter at Lenox Wealth Advisors added. “Fiscal and monetary stimulus may have lost their oomph to push markets higher still.”</p>\n<p>Tame economic data, including flat new orders for core capital goods, reinforced the notion that Fed Chairman Jerome Powell is unlikely to hint at a shortened timeline for policy tightening at the virtual Jackson Hole Symposium, due to get underway on Friday.</p>\n<p>“(The) expectation is that Fed won’t scare markets, and will announce only a cautious tapering,” Carter said.</p>\n<p>The Dow Jones Industrial Average rose 39.24 points, or 0.11%, to 35,405.5, the S&amp;P 500 gained 9.96 points, or 0.22%, to 4,496.19 and the Nasdaq Composite added 22.06 points, or 0.15%, to 15,041.86.</p>\n<p>Financials were the clear winners among 11 major sectors in the S&amp;P 500, gaining more than 1%. Healthcare stocks suffered the largest percentage decline.</p>\n<p>Chipmakers Nvidia Corp and Applied Materials rose 1.9% and 1.2%, respectively, and along with mega-cap growth stocks Alphabet Inc, Tesla Inc and Facebook Inc, provided the biggest boost to the Nasdaq.</p>\n<p>Nordstrom Inc tumbled 17.6% after the department store operator posted a 6% decline in quarterly revenue from pre-pandemic levels.</p>\n<p>Dick’s Sporting Goods Inc announced a special dividend and raised its annual sales and profit forecast, sending its shares surging 13.3%.</p>\n<p>Advancing issues outnumbered declining ones on the NYSE by a 1.49-to-1 ratio; on Nasdaq, a 1.31-to-1 ratio favored advancers.</p>\n<p>The S&amp;P 500 posted 63 new 52-week highs and one new low; the Nasdaq Composite recorded 125 new highs and 33 new lows.</p>\n<p>Volume on U.S. exchanges was 8.29 billion shares, compared with the 9.00 billion average over the last 20 trading days.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>S&P 500, Nasdaq notch all-time closing highs ahead of Jackson Hole</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nS&P 500, Nasdaq notch all-time closing highs ahead of Jackson Hole\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-26 07:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.reuters.com/article/us-usa-stocks/sp-500-nasdaq-notch-all-time-closing-highs-ahead-of-jackson-hole-idUSKBN2FQ0Y4><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>NEW YORK (Reuters) - Wall Street gained ground again on Wednesday, with chipmakers and financials helping to push the S&P 500 and the Nasdaq to record closing highs as investors look to the upcoming ...</p>\n\n<a href=\"https://www.reuters.com/article/us-usa-stocks/sp-500-nasdaq-notch-all-time-closing-highs-ahead-of-jackson-hole-idUSKBN2FQ0Y4\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JWN":"诺德斯特龙","NVDA":"英伟达",".DJI":"道琼斯",".IXIC":"NASDAQ Composite",".SPX":"S&P 500 Index"},"source_url":"https://www.reuters.com/article/us-usa-stocks/sp-500-nasdaq-notch-all-time-closing-highs-ahead-of-jackson-hole-idUSKBN2FQ0Y4","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1197778368","content_text":"NEW YORK (Reuters) - Wall Street gained ground again on Wednesday, with chipmakers and financials helping to push the S&P 500 and the Nasdaq to record closing highs as investors look to the upcoming Jackson Hole Symposium for assurances that Federal Reserve’s timeline for policy tightening remains intact.\nWith few negative catalysts to sour the risk-on sentiment, all three major U.S. indexes ended the session modestly higher.\n“Positive news on vaccination approvals, and expectations that the Fed won’t shock markets at Jackson Hole, are helping to keep equity prices higher,” said David Carter, chief investment officer at Lenox Wealth Advisors in New York, who added “it’s a very quiet market as many investors are sitting on the beach this week.”\nRising U.S. Treasury yields boosted rate sensitive financials, and sectors that stand to gain most from economic revival - smallcaps, chips and transports - were outperforming the broader market.\nDays after the Food and Drug Administration gave full approval to the Pfizer-BioNTech COVID-19 vaccine, companies and institutions are moving toward either mandated inoculation, or penalization for those who forego the shot.\nThe Pentagon and Delta Air Lines are the latest to enact such measures, with Ford Motor Co and others potentially following suit.\nFor an interactive graphic on global vaccine deployment and new infection rates, click here.\nThe session marked the S&P 500’s 51st record high close so far this year.\nAnalysts polled by Reuters, however, see the stock market staying rangebound for the remainder of 2021, with the S&P 500 ending the year little changed as the pandemic recovery, along with corporate earnings growth, lose steam.\n“Following a long run, equity indexes have cooled off as the next engine of growth is unclear,” Carter at Lenox Wealth Advisors added. “Fiscal and monetary stimulus may have lost their oomph to push markets higher still.”\nTame economic data, including flat new orders for core capital goods, reinforced the notion that Fed Chairman Jerome Powell is unlikely to hint at a shortened timeline for policy tightening at the virtual Jackson Hole Symposium, due to get underway on Friday.\n“(The) expectation is that Fed won’t scare markets, and will announce only a cautious tapering,” Carter said.\nThe Dow Jones Industrial Average rose 39.24 points, or 0.11%, to 35,405.5, the S&P 500 gained 9.96 points, or 0.22%, to 4,496.19 and the Nasdaq Composite added 22.06 points, or 0.15%, to 15,041.86.\nFinancials were the clear winners among 11 major sectors in the S&P 500, gaining more than 1%. Healthcare stocks suffered the largest percentage decline.\nChipmakers Nvidia Corp and Applied Materials rose 1.9% and 1.2%, respectively, and along with mega-cap growth stocks Alphabet Inc, Tesla Inc and Facebook Inc, provided the biggest boost to the Nasdaq.\nNordstrom Inc tumbled 17.6% after the department store operator posted a 6% decline in quarterly revenue from pre-pandemic levels.\nDick’s Sporting Goods Inc announced a special dividend and raised its annual sales and profit forecast, sending its shares surging 13.3%.\nAdvancing issues outnumbered declining ones on the NYSE by a 1.49-to-1 ratio; on Nasdaq, a 1.31-to-1 ratio favored advancers.\nThe S&P 500 posted 63 new 52-week highs and one new low; the Nasdaq Composite recorded 125 new highs and 33 new lows.\nVolume on U.S. exchanges was 8.29 billion shares, compared with the 9.00 billion average over the last 20 trading days.","news_type":1},"isVote":1,"tweetType":1,"viewCount":314,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":808413442,"gmtCreate":1627605666786,"gmtModify":1703493155582,"author":{"id":"4088497713200830","authorId":"4088497713200830","name":"skxrena","avatar":"https://static.tigerbbs.com/bcd0597b7a18627a33a524d8ac6dd51d","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4088497713200830","idStr":"4088497713200830"},"themes":[],"htmlText":"cool","listText":"cool","text":"cool","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":3,"repostSize":0,"link":"https://ttm.financial/post/808413442","repostId":"2155181160","repostType":4,"isVote":1,"tweetType":1,"viewCount":502,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":172742406,"gmtCreate":1626996536805,"gmtModify":1703481953029,"author":{"id":"4088497713200830","authorId":"4088497713200830","name":"skxrena","avatar":"https://static.tigerbbs.com/bcd0597b7a18627a33a524d8ac6dd51d","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4088497713200830","idStr":"4088497713200830"},"themes":[],"htmlText":"awesoms","listText":"awesoms","text":"awesoms","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/172742406","repostId":"2153670096","repostType":4,"isVote":1,"tweetType":1,"viewCount":238,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":178281707,"gmtCreate":1626823709009,"gmtModify":1703765744606,"author":{"id":"4088497713200830","authorId":"4088497713200830","name":"skxrena","avatar":"https://static.tigerbbs.com/bcd0597b7a18627a33a524d8ac6dd51d","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4088497713200830","idStr":"4088497713200830"},"themes":[],"htmlText":"great!","listText":"great!","text":"great!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/178281707","repostId":"2153924256","repostType":4,"isVote":1,"tweetType":1,"viewCount":295,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":145747146,"gmtCreate":1626250091585,"gmtModify":1703756323943,"author":{"id":"4088497713200830","authorId":"4088497713200830","name":"skxrena","avatar":"https://static.tigerbbs.com/bcd0597b7a18627a33a524d8ac6dd51d","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4088497713200830","idStr":"4088497713200830"},"themes":[],"htmlText":"awesome","listText":"awesome","text":"awesome","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/145747146","repostId":"1158281742","repostType":4,"repost":{"id":"1158281742","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1626249848,"share":"https://ttm.financial/m/news/1158281742?lang=&edition=fundamental","pubTime":"2021-07-14 16:04","market":"us","language":"en","title":"Apple shares rises nearly 1% in premarket trading.","url":"https://stock-news.laohu8.com/highlight/detail?id=1158281742","media":"Tiger Newspress","summary":"Apple shares rises nearly 1% in premarket trading.\nApple Inc. has asked suppliers to build as many a","content":"<p>Apple&nbsp;shares rises nearly&nbsp;1% in premarket&nbsp;trading.</p>\n<p><img src=\"https://static.tigerbbs.com/35d519e7b8520bdf005ef08215187349\" tg-width=\"1290\" tg-height=\"619\" referrerpolicy=\"no-referrer\">Apple Inc. has asked suppliers to build as many as 90 million next-generation iPhones this year, a sharp increase from its 2020 iPhone shipments, according to people with knowledge of the matter.</p>\n<p>The Cupertino, California-based tech giant has maintained a consistent level in recent years of roughly 75 million units for the initial run from a device’s launch through the end of the year. The upgraded forecast for 2021 would suggest the company anticipates its first iPhone launch since the rollout of Covid-19 vaccines will unlock additional demand. The next iPhones will be Apple’s second with 5G, a key enticement pushing users to upgrade.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Apple shares rises nearly 1% in premarket trading.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nApple shares rises nearly 1% in premarket trading.\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-07-14 16:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Apple&nbsp;shares rises nearly&nbsp;1% in premarket&nbsp;trading.</p>\n<p><img src=\"https://static.tigerbbs.com/35d519e7b8520bdf005ef08215187349\" tg-width=\"1290\" tg-height=\"619\" referrerpolicy=\"no-referrer\">Apple Inc. has asked suppliers to build as many as 90 million next-generation iPhones this year, a sharp increase from its 2020 iPhone shipments, according to people with knowledge of the matter.</p>\n<p>The Cupertino, California-based tech giant has maintained a consistent level in recent years of roughly 75 million units for the initial run from a device’s launch through the end of the year. The upgraded forecast for 2021 would suggest the company anticipates its first iPhone launch since the rollout of Covid-19 vaccines will unlock additional demand. The next iPhones will be Apple’s second with 5G, a key enticement pushing users to upgrade.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AAPL":"苹果"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1158281742","content_text":"Apple shares rises nearly 1% in premarket trading.\nApple Inc. has asked suppliers to build as many as 90 million next-generation iPhones this year, a sharp increase from its 2020 iPhone shipments, according to people with knowledge of the matter.\nThe Cupertino, California-based tech giant has maintained a consistent level in recent years of roughly 75 million units for the initial run from a device’s launch through the end of the year. The upgraded forecast for 2021 would suggest the company anticipates its first iPhone launch since the rollout of Covid-19 vaccines will unlock additional demand. The next iPhones will be Apple’s second with 5G, a key enticement pushing users to upgrade.","news_type":1},"isVote":1,"tweetType":1,"viewCount":565,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":146552421,"gmtCreate":1626093158163,"gmtModify":1703753170396,"author":{"id":"4088497713200830","authorId":"4088497713200830","name":"skxrena","avatar":"https://static.tigerbbs.com/bcd0597b7a18627a33a524d8ac6dd51d","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4088497713200830","idStr":"4088497713200830"},"themes":[],"htmlText":"good","listText":"good","text":"good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/146552421","repostId":"1156961347","repostType":4,"repost":{"id":"1156961347","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1626091932,"share":"https://ttm.financial/m/news/1156961347?lang=&edition=fundamental","pubTime":"2021-07-12 20:12","market":"us","language":"en","title":"Toplines Before US Market Open on Monday","url":"https://stock-news.laohu8.com/highlight/detail?id=1156961347","media":"Tiger Newspress","summary":"Futures tracking the Dow and the S&P 500 indexes edged lower on Monday after Wall Street rallied to ","content":"<p>Futures tracking the Dow and the S&amp;P 500 indexes edged lower on Monday after Wall Street rallied to new peaks in the previous session, with investors awaiting the start of the second-quarter earning season and a batch of economic data.</p>\n<p>At 8:10 a.m. ET, Dow E-minis were down 122 points, or 0.35%, S&amp;P 500 E-minis were down 7.5 points, or 0.17% and Nasdaq 100 E-minis were up 33.25 points, or 0.22%.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/ac31dda4d4d95330be5d71b8180102d4\" tg-width=\"810\" tg-height=\"265\" referrerpolicy=\"no-referrer\"><span>*Source From Tiger Trade, EST 08:10</span></p>\n<p>Starting Tuesday, earnings reports are due from JPMorgan Chase, Goldman Sachs, Bank of America and other big banks, with market participants looking for early clues on the economy and stocks tied to growth.</p>\n<p>Shares of the big lenders fell between 0.9% and 1.0% in premarket trading.</p>\n<p>Second-quarter earnings for S&amp;P 500 companies are expected to rise 65.8%, according to IBES data from Refinitiv.</p>\n<p><b>Stocks making the biggest moves in the premarket:</b></p>\n<p><b><a href=\"https://laohu8.com/S/SPCE\">Virgin Galactic</a> — </b>Shares of the space company jumped 9% in premarket trading after CEO Richard Branson completed a long-awaited test flight to space on Sunday.It was the first spaceflight to date for Virgin Galactic carrying more than one passenger. Branson also became the first of the billionaire space company founders to ride his own spacecraft, beating Elon Musk and Jeff Bezos.</p>\n<p><b><a href=\"https://laohu8.com/S/CAKE\">Cheesecake Factory</a></b> <b>—</b> The restaurant stock climbed more than 1% in premarket trading after Raymond Jamesupgraded the shares to outperform from market perform. The Wall Street firm said the market is underestimating the comeback for full-service restaurants. Cheesecake Factory shares have fallen about 8% in the past month.</p>\n<p><b><a href=\"https://laohu8.com/S/JWN\">Nordstrom</a></b> <b>— </b>Shares of the department store dipped slightly after the company said Sundayit has acquired a minority stakein four apparel brands owned by the online U.K. fashion house Asos. The brands — Topshop, Topman, Miss Selfridge and the activewear label HIIT — target younger consumers in their 20s. Financial terms of the deal weren't disclosed.</p>\n<p><b><a href=\"https://laohu8.com/S/JPM\">JPMorgan Chase</a></b> <b>,<a href=\"https://laohu8.com/S/BAC\">Bank of America</a> — </b>Major bank stocks traded lower across the board despite expectations for strong earnings reports this week. JPMorgan dipped 0.7%, while Goldman Sachs fell 0.5% and Bank of America shares traded 0.8% lower. The decline came as bond yields continued to drift lower. JPMorgan and&nbsp;Goldman Sachs&nbsp;kick off earnings season with results due out before the bell on Tuesday.&nbsp;Bank of America,&nbsp;Citigroup and&nbsp;Wells Fargo report on Wednesday.</p>\n<p><b><a href=\"https://laohu8.com/S/UAL\">United Continental</a></b> <b>,<a href=\"https://laohu8.com/S/CCL\">Carnival</a> —</b>Shares tied to the economic reopening were slightly weaker in premarket Monday. United Airline fell more than 1% after losing 2.3% month to date. Boeing and Delta Air Line both traded about 1% lower. Carnival, Norwegian Cruise Line and Royal Caribbean all fell over 1%.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Toplines Before US Market Open on Monday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nToplines Before US Market Open on Monday\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-07-12 20:12</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Futures tracking the Dow and the S&amp;P 500 indexes edged lower on Monday after Wall Street rallied to new peaks in the previous session, with investors awaiting the start of the second-quarter earning season and a batch of economic data.</p>\n<p>At 8:10 a.m. ET, Dow E-minis were down 122 points, or 0.35%, S&amp;P 500 E-minis were down 7.5 points, or 0.17% and Nasdaq 100 E-minis were up 33.25 points, or 0.22%.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/ac31dda4d4d95330be5d71b8180102d4\" tg-width=\"810\" tg-height=\"265\" referrerpolicy=\"no-referrer\"><span>*Source From Tiger Trade, EST 08:10</span></p>\n<p>Starting Tuesday, earnings reports are due from JPMorgan Chase, Goldman Sachs, Bank of America and other big banks, with market participants looking for early clues on the economy and stocks tied to growth.</p>\n<p>Shares of the big lenders fell between 0.9% and 1.0% in premarket trading.</p>\n<p>Second-quarter earnings for S&amp;P 500 companies are expected to rise 65.8%, according to IBES data from Refinitiv.</p>\n<p><b>Stocks making the biggest moves in the premarket:</b></p>\n<p><b><a href=\"https://laohu8.com/S/SPCE\">Virgin Galactic</a> — </b>Shares of the space company jumped 9% in premarket trading after CEO Richard Branson completed a long-awaited test flight to space on Sunday.It was the first spaceflight to date for Virgin Galactic carrying more than one passenger. Branson also became the first of the billionaire space company founders to ride his own spacecraft, beating Elon Musk and Jeff Bezos.</p>\n<p><b><a href=\"https://laohu8.com/S/CAKE\">Cheesecake Factory</a></b> <b>—</b> The restaurant stock climbed more than 1% in premarket trading after Raymond Jamesupgraded the shares to outperform from market perform. The Wall Street firm said the market is underestimating the comeback for full-service restaurants. Cheesecake Factory shares have fallen about 8% in the past month.</p>\n<p><b><a href=\"https://laohu8.com/S/JWN\">Nordstrom</a></b> <b>— </b>Shares of the department store dipped slightly after the company said Sundayit has acquired a minority stakein four apparel brands owned by the online U.K. fashion house Asos. The brands — Topshop, Topman, Miss Selfridge and the activewear label HIIT — target younger consumers in their 20s. Financial terms of the deal weren't disclosed.</p>\n<p><b><a href=\"https://laohu8.com/S/JPM\">JPMorgan Chase</a></b> <b>,<a href=\"https://laohu8.com/S/BAC\">Bank of America</a> — </b>Major bank stocks traded lower across the board despite expectations for strong earnings reports this week. JPMorgan dipped 0.7%, while Goldman Sachs fell 0.5% and Bank of America shares traded 0.8% lower. The decline came as bond yields continued to drift lower. JPMorgan and&nbsp;Goldman Sachs&nbsp;kick off earnings season with results due out before the bell on Tuesday.&nbsp;Bank of America,&nbsp;Citigroup and&nbsp;Wells Fargo report on Wednesday.</p>\n<p><b><a href=\"https://laohu8.com/S/UAL\">United Continental</a></b> <b>,<a href=\"https://laohu8.com/S/CCL\">Carnival</a> —</b>Shares tied to the economic reopening were slightly weaker in premarket Monday. United Airline fell more than 1% after losing 2.3% month to date. Boeing and Delta Air Line both traded about 1% lower. Carnival, Norwegian Cruise Line and Royal Caribbean all fell over 1%.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".DJI":"道琼斯","JWN":"诺德斯特龙","BAC":"美国银行",".IXIC":"NASDAQ Composite","UAL":"联合大陆航空","JPM":"摩根大通","SPCE":"维珍银河","CAKE":"芝乐坊餐馆",".SPX":"S&P 500 Index","CCL":"嘉年华邮轮"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1156961347","content_text":"Futures tracking the Dow and the S&P 500 indexes edged lower on Monday after Wall Street rallied to new peaks in the previous session, with investors awaiting the start of the second-quarter earning season and a batch of economic data.\nAt 8:10 a.m. ET, Dow E-minis were down 122 points, or 0.35%, S&P 500 E-minis were down 7.5 points, or 0.17% and Nasdaq 100 E-minis were up 33.25 points, or 0.22%.\n*Source From Tiger Trade, EST 08:10\nStarting Tuesday, earnings reports are due from JPMorgan Chase, Goldman Sachs, Bank of America and other big banks, with market participants looking for early clues on the economy and stocks tied to growth.\nShares of the big lenders fell between 0.9% and 1.0% in premarket trading.\nSecond-quarter earnings for S&P 500 companies are expected to rise 65.8%, according to IBES data from Refinitiv.\nStocks making the biggest moves in the premarket:\nVirgin Galactic — Shares of the space company jumped 9% in premarket trading after CEO Richard Branson completed a long-awaited test flight to space on Sunday.It was the first spaceflight to date for Virgin Galactic carrying more than one passenger. Branson also became the first of the billionaire space company founders to ride his own spacecraft, beating Elon Musk and Jeff Bezos.\nCheesecake Factory — The restaurant stock climbed more than 1% in premarket trading after Raymond Jamesupgraded the shares to outperform from market perform. The Wall Street firm said the market is underestimating the comeback for full-service restaurants. Cheesecake Factory shares have fallen about 8% in the past month.\nNordstrom — Shares of the department store dipped slightly after the company said Sundayit has acquired a minority stakein four apparel brands owned by the online U.K. fashion house Asos. The brands — Topshop, Topman, Miss Selfridge and the activewear label HIIT — target younger consumers in their 20s. Financial terms of the deal weren't disclosed.\nJPMorgan Chase ,Bank of America — Major bank stocks traded lower across the board despite expectations for strong earnings reports this week. JPMorgan dipped 0.7%, while Goldman Sachs fell 0.5% and Bank of America shares traded 0.8% lower. The decline came as bond yields continued to drift lower. JPMorgan and Goldman Sachs kick off earnings season with results due out before the bell on Tuesday. Bank of America, Citigroup and Wells Fargo report on Wednesday.\nUnited Continental ,Carnival —Shares tied to the economic reopening were slightly weaker in premarket Monday. United Airline fell more than 1% after losing 2.3% month to date. Boeing and Delta Air Line both traded about 1% lower. Carnival, Norwegian Cruise Line and Royal Caribbean all fell over 1%.","news_type":1},"isVote":1,"tweetType":1,"viewCount":319,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":810166459,"gmtCreate":1629953230871,"gmtModify":1676530182952,"author":{"id":"4088497713200830","authorId":"4088497713200830","name":"skxrena","avatar":"https://static.tigerbbs.com/bcd0597b7a18627a33a524d8ac6dd51d","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4088497713200830","authorIdStr":"4088497713200830"},"themes":[],"htmlText":"good","listText":"good","text":"good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/810166459","repostId":"1197778368","repostType":4,"repost":{"id":"1197778368","pubTimestamp":1629932731,"share":"https://ttm.financial/m/news/1197778368?lang=&edition=fundamental","pubTime":"2021-08-26 07:05","market":"us","language":"en","title":"S&P 500, Nasdaq notch all-time closing highs ahead of Jackson Hole","url":"https://stock-news.laohu8.com/highlight/detail?id=1197778368","media":"Reuters","summary":"NEW YORK (Reuters) - Wall Street gained ground again on Wednesday, with chipmakers and financials he","content":"<p>NEW YORK (Reuters) - Wall Street gained ground again on Wednesday, with chipmakers and financials helping to push the S&amp;P 500 and the Nasdaq to record closing highs as investors look to the upcoming Jackson Hole Symposium for assurances that Federal Reserve’s timeline for policy tightening remains intact.</p>\n<p>With few negative catalysts to sour the risk-on sentiment, all three major U.S. indexes ended the session modestly higher.</p>\n<p>“Positive news on vaccination approvals, and expectations that the Fed won’t shock markets at Jackson Hole, are helping to keep equity prices higher,” said David Carter, chief investment officer at Lenox Wealth Advisors in New York, who added “it’s a very quiet market as many investors are sitting on the beach this week.”</p>\n<p>Rising U.S. Treasury yields boosted rate sensitive financials, and sectors that stand to gain most from economic revival - smallcaps, chips and transports - were outperforming the broader market.</p>\n<p>Days after the Food and Drug Administration gave full approval to the Pfizer-BioNTech COVID-19 vaccine, companies and institutions are moving toward either mandated inoculation, or penalization for those who forego the shot.</p>\n<p>The Pentagon and Delta Air Lines are the latest to enact such measures, with Ford Motor Co and others potentially following suit.</p>\n<p>For an interactive graphic on global vaccine deployment and new infection rates, click here.</p>\n<p>The session marked the S&amp;P 500’s 51st record high close so far this year.</p>\n<p>Analysts polled by Reuters, however, see the stock market staying rangebound for the remainder of 2021, with the S&amp;P 500 ending the year little changed as the pandemic recovery, along with corporate earnings growth, lose steam.</p>\n<p>“Following a long run, equity indexes have cooled off as the next engine of growth is unclear,” Carter at Lenox Wealth Advisors added. “Fiscal and monetary stimulus may have lost their oomph to push markets higher still.”</p>\n<p>Tame economic data, including flat new orders for core capital goods, reinforced the notion that Fed Chairman Jerome Powell is unlikely to hint at a shortened timeline for policy tightening at the virtual Jackson Hole Symposium, due to get underway on Friday.</p>\n<p>“(The) expectation is that Fed won’t scare markets, and will announce only a cautious tapering,” Carter said.</p>\n<p>The Dow Jones Industrial Average rose 39.24 points, or 0.11%, to 35,405.5, the S&amp;P 500 gained 9.96 points, or 0.22%, to 4,496.19 and the Nasdaq Composite added 22.06 points, or 0.15%, to 15,041.86.</p>\n<p>Financials were the clear winners among 11 major sectors in the S&amp;P 500, gaining more than 1%. Healthcare stocks suffered the largest percentage decline.</p>\n<p>Chipmakers Nvidia Corp and Applied Materials rose 1.9% and 1.2%, respectively, and along with mega-cap growth stocks Alphabet Inc, Tesla Inc and Facebook Inc, provided the biggest boost to the Nasdaq.</p>\n<p>Nordstrom Inc tumbled 17.6% after the department store operator posted a 6% decline in quarterly revenue from pre-pandemic levels.</p>\n<p>Dick’s Sporting Goods Inc announced a special dividend and raised its annual sales and profit forecast, sending its shares surging 13.3%.</p>\n<p>Advancing issues outnumbered declining ones on the NYSE by a 1.49-to-1 ratio; on Nasdaq, a 1.31-to-1 ratio favored advancers.</p>\n<p>The S&amp;P 500 posted 63 new 52-week highs and one new low; the Nasdaq Composite recorded 125 new highs and 33 new lows.</p>\n<p>Volume on U.S. exchanges was 8.29 billion shares, compared with the 9.00 billion average over the last 20 trading days.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>S&P 500, Nasdaq notch all-time closing highs ahead of Jackson Hole</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nS&P 500, Nasdaq notch all-time closing highs ahead of Jackson Hole\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-26 07:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.reuters.com/article/us-usa-stocks/sp-500-nasdaq-notch-all-time-closing-highs-ahead-of-jackson-hole-idUSKBN2FQ0Y4><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>NEW YORK (Reuters) - Wall Street gained ground again on Wednesday, with chipmakers and financials helping to push the S&P 500 and the Nasdaq to record closing highs as investors look to the upcoming ...</p>\n\n<a href=\"https://www.reuters.com/article/us-usa-stocks/sp-500-nasdaq-notch-all-time-closing-highs-ahead-of-jackson-hole-idUSKBN2FQ0Y4\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JWN":"诺德斯特龙","NVDA":"英伟达",".DJI":"道琼斯",".IXIC":"NASDAQ Composite",".SPX":"S&P 500 Index"},"source_url":"https://www.reuters.com/article/us-usa-stocks/sp-500-nasdaq-notch-all-time-closing-highs-ahead-of-jackson-hole-idUSKBN2FQ0Y4","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1197778368","content_text":"NEW YORK (Reuters) - Wall Street gained ground again on Wednesday, with chipmakers and financials helping to push the S&P 500 and the Nasdaq to record closing highs as investors look to the upcoming Jackson Hole Symposium for assurances that Federal Reserve’s timeline for policy tightening remains intact.\nWith few negative catalysts to sour the risk-on sentiment, all three major U.S. indexes ended the session modestly higher.\n“Positive news on vaccination approvals, and expectations that the Fed won’t shock markets at Jackson Hole, are helping to keep equity prices higher,” said David Carter, chief investment officer at Lenox Wealth Advisors in New York, who added “it’s a very quiet market as many investors are sitting on the beach this week.”\nRising U.S. Treasury yields boosted rate sensitive financials, and sectors that stand to gain most from economic revival - smallcaps, chips and transports - were outperforming the broader market.\nDays after the Food and Drug Administration gave full approval to the Pfizer-BioNTech COVID-19 vaccine, companies and institutions are moving toward either mandated inoculation, or penalization for those who forego the shot.\nThe Pentagon and Delta Air Lines are the latest to enact such measures, with Ford Motor Co and others potentially following suit.\nFor an interactive graphic on global vaccine deployment and new infection rates, click here.\nThe session marked the S&P 500’s 51st record high close so far this year.\nAnalysts polled by Reuters, however, see the stock market staying rangebound for the remainder of 2021, with the S&P 500 ending the year little changed as the pandemic recovery, along with corporate earnings growth, lose steam.\n“Following a long run, equity indexes have cooled off as the next engine of growth is unclear,” Carter at Lenox Wealth Advisors added. “Fiscal and monetary stimulus may have lost their oomph to push markets higher still.”\nTame economic data, including flat new orders for core capital goods, reinforced the notion that Fed Chairman Jerome Powell is unlikely to hint at a shortened timeline for policy tightening at the virtual Jackson Hole Symposium, due to get underway on Friday.\n“(The) expectation is that Fed won’t scare markets, and will announce only a cautious tapering,” Carter said.\nThe Dow Jones Industrial Average rose 39.24 points, or 0.11%, to 35,405.5, the S&P 500 gained 9.96 points, or 0.22%, to 4,496.19 and the Nasdaq Composite added 22.06 points, or 0.15%, to 15,041.86.\nFinancials were the clear winners among 11 major sectors in the S&P 500, gaining more than 1%. Healthcare stocks suffered the largest percentage decline.\nChipmakers Nvidia Corp and Applied Materials rose 1.9% and 1.2%, respectively, and along with mega-cap growth stocks Alphabet Inc, Tesla Inc and Facebook Inc, provided the biggest boost to the Nasdaq.\nNordstrom Inc tumbled 17.6% after the department store operator posted a 6% decline in quarterly revenue from pre-pandemic levels.\nDick’s Sporting Goods Inc announced a special dividend and raised its annual sales and profit forecast, sending its shares surging 13.3%.\nAdvancing issues outnumbered declining ones on the NYSE by a 1.49-to-1 ratio; on Nasdaq, a 1.31-to-1 ratio favored advancers.\nThe S&P 500 posted 63 new 52-week highs and one new low; the Nasdaq Composite recorded 125 new highs and 33 new lows.\nVolume on U.S. exchanges was 8.29 billion shares, compared with the 9.00 billion average over the last 20 trading days.","news_type":1},"isVote":1,"tweetType":1,"viewCount":314,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":808413442,"gmtCreate":1627605666786,"gmtModify":1703493155582,"author":{"id":"4088497713200830","authorId":"4088497713200830","name":"skxrena","avatar":"https://static.tigerbbs.com/bcd0597b7a18627a33a524d8ac6dd51d","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4088497713200830","authorIdStr":"4088497713200830"},"themes":[],"htmlText":"cool","listText":"cool","text":"cool","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":3,"repostSize":0,"link":"https://ttm.financial/post/808413442","repostId":"2155181160","repostType":4,"repost":{"id":"2155181160","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1627604809,"share":"https://ttm.financial/m/news/2155181160?lang=&edition=fundamental","pubTime":"2021-07-30 08:26","market":"us","language":"en","title":"Qualtrics to acquire Clarabridge for $1.1 bln in stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2155181160","media":"Reuters","summary":"July 29 (Reuters) - Qualtrics International Inc on Thursday said it would acquire privately held Cla","content":"<p>July 29 (Reuters) - <a href=\"https://laohu8.com/S/XM\">Qualtrics International</a> Inc on Thursday said it would acquire privately held Clarabridge for $1.1 billion in stock.</p>\n<p>Qualtrics, which was spun out of <a href=\"https://laohu8.com/S/SAP\">SAP SE</a> earlier this year and remains majority-controlled by the German software company, makes software that helps companies gather feedback from customers about their experiences with products and services.</p>\n<p>Most of Provo, Utah-based Qualtrics' software uses online surveys to gather that feedback directly from customers.</p>\n<p>Qualtrics said Reston, Virgina-based Clarabridge augments that capability by gathering feedback indirectly. Clarabridge's software uses artificial intelligence to comb indirect sources like social media posts and customer support calls for information about how customers felt about their experience with a brand.</p>\n<p>\"Customers, employees, they're sharing feedback about companies everywhere. They're doing on social media, they're doing it on support calls, they're doing it on chats, they're doing it in product reviews - everywhere,\" Qualtrics Chief Executive Zig Serafin told Reuters in an interview.</p>\n<p>Serafin said that the key to Clarabridge's technology is its ability to understand human language. For example, it can detect not just that a customer on a support chat is upset, but how intensely upset the customer is - which can help the company decide which steps to take to remedy the problem.</p>\n<p>\"What it does is it takes the category that we've been building to the next level,\" Serafin said.</p>\n<p>The $1.125 billion acquisition price will be paid via fixed number of Qualtrics' class A shares at $37.33 per share, slightly below Qualtrics closing price of $39.81 per share on Wednesday.</p>\n<p>Qualtrics said that privately held Clarabridge had about $100 million in annual revenue, with a sales growth rate of about 25%.</p>\n<p>Founded in 2006, Clarabridge raised about $125 million in venture capital prior to the deal from investors including General Catalyst, Summit Ventures and Boulder Ventures, according to Crunchbase.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Qualtrics to acquire Clarabridge for $1.1 bln in stock</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nQualtrics to acquire Clarabridge for $1.1 bln in stock\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-07-30 08:26</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>July 29 (Reuters) - <a href=\"https://laohu8.com/S/XM\">Qualtrics International</a> Inc on Thursday said it would acquire privately held Clarabridge for $1.1 billion in stock.</p>\n<p>Qualtrics, which was spun out of <a href=\"https://laohu8.com/S/SAP\">SAP SE</a> earlier this year and remains majority-controlled by the German software company, makes software that helps companies gather feedback from customers about their experiences with products and services.</p>\n<p>Most of Provo, Utah-based Qualtrics' software uses online surveys to gather that feedback directly from customers.</p>\n<p>Qualtrics said Reston, Virgina-based Clarabridge augments that capability by gathering feedback indirectly. Clarabridge's software uses artificial intelligence to comb indirect sources like social media posts and customer support calls for information about how customers felt about their experience with a brand.</p>\n<p>\"Customers, employees, they're sharing feedback about companies everywhere. They're doing on social media, they're doing it on support calls, they're doing it on chats, they're doing it in product reviews - everywhere,\" Qualtrics Chief Executive Zig Serafin told Reuters in an interview.</p>\n<p>Serafin said that the key to Clarabridge's technology is its ability to understand human language. For example, it can detect not just that a customer on a support chat is upset, but how intensely upset the customer is - which can help the company decide which steps to take to remedy the problem.</p>\n<p>\"What it does is it takes the category that we've been building to the next level,\" Serafin said.</p>\n<p>The $1.125 billion acquisition price will be paid via fixed number of Qualtrics' class A shares at $37.33 per share, slightly below Qualtrics closing price of $39.81 per share on Wednesday.</p>\n<p>Qualtrics said that privately held Clarabridge had about $100 million in annual revenue, with a sales growth rate of about 25%.</p>\n<p>Founded in 2006, Clarabridge raised about $125 million in venture capital prior to the deal from investors including General Catalyst, Summit Ventures and Boulder Ventures, according to Crunchbase.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"XM":"Qualtrics International"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2155181160","content_text":"July 29 (Reuters) - Qualtrics International Inc on Thursday said it would acquire privately held Clarabridge for $1.1 billion in stock.\nQualtrics, which was spun out of SAP SE earlier this year and remains majority-controlled by the German software company, makes software that helps companies gather feedback from customers about their experiences with products and services.\nMost of Provo, Utah-based Qualtrics' software uses online surveys to gather that feedback directly from customers.\nQualtrics said Reston, Virgina-based Clarabridge augments that capability by gathering feedback indirectly. Clarabridge's software uses artificial intelligence to comb indirect sources like social media posts and customer support calls for information about how customers felt about their experience with a brand.\n\"Customers, employees, they're sharing feedback about companies everywhere. They're doing on social media, they're doing it on support calls, they're doing it on chats, they're doing it in product reviews - everywhere,\" Qualtrics Chief Executive Zig Serafin told Reuters in an interview.\nSerafin said that the key to Clarabridge's technology is its ability to understand human language. For example, it can detect not just that a customer on a support chat is upset, but how intensely upset the customer is - which can help the company decide which steps to take to remedy the problem.\n\"What it does is it takes the category that we've been building to the next level,\" Serafin said.\nThe $1.125 billion acquisition price will be paid via fixed number of Qualtrics' class A shares at $37.33 per share, slightly below Qualtrics closing price of $39.81 per share on Wednesday.\nQualtrics said that privately held Clarabridge had about $100 million in annual revenue, with a sales growth rate of about 25%.\nFounded in 2006, Clarabridge raised about $125 million in venture capital prior to the deal from investors including General Catalyst, Summit Ventures and Boulder Ventures, according to Crunchbase.","news_type":1},"isVote":1,"tweetType":1,"viewCount":502,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":818188354,"gmtCreate":1630384343578,"gmtModify":1676530287871,"author":{"id":"4088497713200830","authorId":"4088497713200830","name":"skxrena","avatar":"https://static.tigerbbs.com/bcd0597b7a18627a33a524d8ac6dd51d","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4088497713200830","authorIdStr":"4088497713200830"},"themes":[],"htmlText":"up please!","listText":"up please!","text":"up please!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/818188354","repostId":"1104186500","repostType":4,"repost":{"id":"1104186500","pubTimestamp":1630377505,"share":"https://ttm.financial/m/news/1104186500?lang=&edition=fundamental","pubTime":"2021-08-31 10:38","market":"us","language":"en","title":"Is AMC Stock A Buy Now? Here's What Fundamentals, Chart Action, Fund Ownership Metrics Say","url":"https://stock-news.laohu8.com/highlight/detail?id=1104186500","media":"investors","summary":"Going to the movies is exciting. But can it match the action by AMC Entertainment(AMC)? Starting the","content":"<p>Going to the movies is exciting. But can it match the action by&nbsp;<b>AMC Entertainment</b>(AMC)? Starting the year at 2 a share,AMC stock skyrocketed more than 36-foldto an all-time high of 72.62 on June 2.</p>\n<p>Even though an epic short squeeze rally hit overdrive in January this year, AMC stock still attracts short sellers.</p>\n<p>Data frombrokerage TradeZero Americafor the week ended July 23 shows AMC Entertainment placed 3rd among stocks trading at least $10 a share and getting sold short the most. A total 14,666 short-sale trades crossed TradeZero's platform at an average price of 38.18 per share. AMC ranked No. 2 for the weeks ended Aug. 20 and Aug. 27; in the most recent week, the broker executed 21,746 trades at an average price of 42.57 per share.</p>\n<p>For weeks, AMC has faced stubborn upside resistance at the21-day exponential moving average. No longer. During the week ended Aug. 27, shares bolted as much as 40% higher for the week before settling for an 18% gain.</p>\n<p>More than 694 million shares exchanged hands during the week, the highest since the week ended June 18.</p>\n<p>With August about to end, AMC shares look well poised to rise four weeks in a row and avoid a two-month slide after the company smashed second-quarter estimates; its net loss of 71 cents a share beat an estimated net loss of 93 cents. Sales rebounded to $444.7 million vs. $18.9 million a year ago, blasting a forecast for $375 million.</p>\n<p><b>Q2 Reaction</b></p>\n<p>In an Aug. 9 news release, AMC Chairman and CEO Adam Aron noted the company raised another $1.25 billion in new equity capital during the quarter; welcomed more than 22 million guests back to its theaters across the globe; and saw successive new pandemic-era box office records on the back of new blockbuster films released over the three-month period.</p>\n<p>AMC stock staged a negative reversal the next day after earnings following an early rally up to its21-day EMA. Please see thisIBD news storyfor more details on second-quarter results.</p>\n<p>Meanwhile, check out the downward-sloping50-day moving average, drawn in red in all IBD charts. It no longer lags the stock price. AMC stock had started to live beneath this vital medium-term level of technical support and resistance. But now AMC shares are showing an encouraging rebound back above the 50-day line (or the&nbsp;10-week moving average&nbsp;on a weekly chart); such a move after a normal breakout from awell-formed basecan present afollow-on entry point.</p>\n<p><b>AMC Stock: Still A Leader In The Stock Market Today</b></p>\n<p>So, given extraordinary gains through late May, is it time to take profits off the table? After all, the May rally displayedelements of a climax run. And now, gains from a recentbuy pointat 14.64 have now shrunk dramatically.</p>\n<p>Or is it a buy now?</p>\n<p>This story examines fundamental, technical and fund ownership factors to determine if the Leawood, Kan., company with 1,004 theaters and 11,041 screens scores a good probability of making more money for stock traders.</p>\n<p>After Memorial Day, AMC jammed nearly 23% higher after the company announced an agreement to sell 8.5 million shares at $27.15 per share to Mudrick Capital. AMC said the proceeds would go toward strategic acquisitions of \"additional theatre leases, as well as investments to enhance the consumer appeal of AMC's existing theatres.\"</p>\n<p>Some of that money could also go toward paying down debt.</p>\n<p>On June 3, shares at one point fell more than 30% on news the company plans to sell up to 11.55 million shares — or roughly 2.6% of the total common shares outstanding. AMC raised $587 million. On July 6, the company decided toshelve a plan to sell more shares to the public.</p>\n<p><b>Are The Shorts Covering AMC Stock?</b></p>\n<p>Meantime, consider this stat: Prior to the giant gain on June 2, over just five sessions of trade (May 24 to 28), AMC obliterated the short sellers by rising as much as 203%. In the week ended June 4, AMC stock almost finished up 100% or more for a second straight week. Incredible.</p>\n<p>Earlier this year, WallStreetBets chat-room traders on Reddit joined in unison in buying shares and bullish call options in AMC stock. They did the same in a band of other companies that had been heavily sold short and struggling.</p>\n<p>When a stock shows ahigh level of short interestand is getting bid up, you can almost count on a chain reaction of buying to occur. Why? Short sellers, betting on a decline in the stock, often have to do an about-face. They cover their short position by buying back shares.</p>\n<p>According to data analyzed byMarketSmith,short interest— shares sold short by individual and professional investors —&nbsp; stands at 0.9 times AMC stock's daily average volume of 99 million shares, or roughly 89 million shares. Short interest, in other words, has climbed back to nearly 17% of the stock's entire float. That's down from 21% in the spring.</p>\n<p>The NYSE publishes data on short sale positions only twice a month. Plus, the short coverage ratio can be skewed by dramatic changes in daily share turnover. The above data also does not consider any shares that may have been sold short in dark pools.</p>\n<p>TheInvestor's Business Daily teamwill keep close watch for any signs that short interest has dropped lately.</p>\n<p>Since late January, AMC stock has followed an extreme zigzag path.&nbsp;Just two weeks after that 20.36 peak, AMC crashed. Shares fell to as low as 5.26. Then came a huge second wave of buying, sending shares back in the low teens.</p>\n<p>Week to week, the stock (pumping its market value this year to as high as $36 billion on 513 million shares outstanding and a float of 508 million) has lately seen its overall price range narrow. That's good as thenew base formed.</p>\n<p><b>Will AMC Stock Keep Rallying In The Long Term?</b></p>\n<p>AMC fans are betting on a turnaround in fortunes. In 2020, AMC lost $16.15 a share. Over the past five quarters, the company's sales have shrunk 22% to as much as 99% vs. year-ago levels. Such results would normally devastate most companies.</p>\n<p>Wall Street now expects net losses of $2.85 a share for 2021, a far cry from the unadjusted net loss of $16.15 it suffered last year. And the Street sees net losses shrinking further in 2022, to 83 cents a share. Recently, that estimate stood at a net loss of 96 cents.</p>\n<p>With big sales expected to arrive, you can expect cash flows to greatly improve.</p>\n<p>Some observers have expressed concern over the company's debt load ($5.5 billion in borrowings due one year from now or longer, as of June 30) vs. total assets ($11.3 billion) on the balance sheet. While the company generated $1.21 billion in net cash from financing activities in the first six months of 2021, AMC still posted a negative free cash flow of -$252 million. Operating cash flow was a net outflow of $234 million.</p>\n<p>Key IBD Ratings</p>\n<p>The last time AMC paid a dividend came on March 23, 2020, at 3 cents per common share. If the company were to resume this cash payout, shareholders could attain an annualized 0.9% yield at the current price near 14 a share.</p>\n<p>For now, AMC scores poorly in many of IBD's proprietary ratings. They include an improved 44Earnings Per Share Ratingon a scale of 1 to 99; an improved yet still weak D for Sales + Profit Margins + Return on Equity (SMR) Rating; and a rising 64Composite Rating&nbsp;on a scale of 1 (wizened) to 99 (wizardly).</p>\n<p>Meanwhile, AMC's movies industry group has dropped deep back into the bottom half of IBD's197 industry groupsin terms of six-month price-weighted performance. Mutual funds owning a stake in AMC have recently risen to as high as 232 at the end of the June-ended quarter vs. 186 in Q4 of 2020. Some portfolio managers are clearly eager to accumulate shares.</p>\n<p>You can check the daily price-weighted performance of all IBD industry groups, as well as the rankings based on six-month performance, atIBD Data Tables.</p>\n<p>AMC Stock Forecast</p>\n<p>When choosing growth stocks for the biggest potential gains based on theCAN SLIM investment paradigm, your chances of finding a true market leader improve when you focus on those with aComposite Ratingof 90 or higher. Shooting for a 95 or higher, particularly at the start of a new bull market, is even better.</p>\n<p>However, given that AMC stock is a turnaround play, it makes sense to place more emphasis on relative strength. AMC has that in spades.</p>\n<p>A 99Relative Strength Ratingon a scale of 1 to 99 means that the company has outperformed 99% of all stocks in the IBD database over the past 12 months. Strong long-term performance? Indeed.The Accumulation/Distribution Rating, meanwhile, shows an excellent A grade on a scale of A to E.</p>\n<p>On the weekly chart and inMarketSmith, watch for therelative strength lineto rise again after falling steeply. The RS line, drawn in blue, compares a stock or ETF's moves vs. the S&amp;P 500. When a stock breaks out of anew base, prefer to see the RS line also running to new high ground. This means that a stock is now outperforming the general market.</p>\n<p>Earlier this year, AMC created a boxy cup-like base over a period of two months. That's plenty of time for asolid cup patternto form. This pattern produces aproper buy pointof 10 cents above the cup's left-side peak of 14.54 on March 18. So in AMC stock's case, thecorrect entrystood at 14.64. You want to see heavy volume on the breakout.</p>\n<p><b>Conclusion: Is It A Buy Now? Or A Sell?</b></p>\n<p>In effect,AMC stockstaged astrong breakouttwice over a short period in May.</p>\n<p>First, AMC had to surpass 14.64 before becoming a new buy. A 20% gain on May 25 sent shares zooming past theproper buy point.&nbsp;The5% buy zonegoes up to 15.37, so the stock quickly got extended.</p>\n<p>As always, control your risk. Not all breakouts work, especially when thestock market uptrend goes under pressure or into a correction. The best time to buy? When IBD notes the stock market in aconfirmed uptrend, it signifies that buying demand is healthy among institutional investors.</p>\n<p>In stock investing, you want the wind at your back, not in your face.</p>\n<p>Back in May, this story suggested keeping a close eye on how AMC stock handles potential upside resistance near 20. In fact, the action since that incredible week ended Jan. 29 could also be viewed as adeep cup pattern. From that vantage point, AMC delivered a second breakout on May 27, surpassing a new 20.46buy pointwith fury.</p>\n<p>To get this ideal entry in acup without handle, simply add 10 cents to the cup's left-side high — in this case, 20.36. On May 27, shares rifled past this entry. For a while, AMC refused to look back. Still, with gains of as much as 501% in just two weeks, it made sense to lock in at least partial profits.</p>\n<p><b>AMC Action Today</b></p>\n<p>AMC had fallen as much as 60% below its 72.62 all-time high. So it does not yet trade at anIBD-style entry point. For those who want to go long, you can watch to see if anew bullish chart patternwill form. For a while, the action began to resemble a rarehigh, tight flag. No longer.</p>\n<p>The current attempt to rebound back above the 10-week moving average, around 39, sparks a newfollow-on buy opportunityfor the intrepid investor.</p>\n<p>However, all in all, AMC is not yet a buy. That could change if shares continue to rally further above the 10-week line with strength and serious volume. Nearly&nbsp; three months since the peak, it is looking more likely that AMC is building anew base, such as thecup without handle.</p>\n<p>And it perhaps will need at least a couple weeks for AMC to build theright side of that new base in bullish fashion.</p>\n<p>Finally, after you buy any stock with solid prospects, always heedthe golden rule of investing. Keeping your losses small keeps you in the investing game for the long haul.</p>","source":"lsy1610449120050","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is AMC Stock A Buy Now? Here's What Fundamentals, Chart Action, Fund Ownership Metrics Say</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs AMC Stock A Buy Now? Here's What Fundamentals, Chart Action, Fund Ownership Metrics Say\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-31 10:38 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.investors.com/research/amc-entertainment-stock-buy-now/?src=A00220><strong>investors</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Going to the movies is exciting. But can it match the action by AMC Entertainment(AMC)? Starting the year at 2 a share,AMC stock skyrocketed more than 36-foldto an all-time high of 72.62 on June 2.\n...</p>\n\n<a href=\"https://www.investors.com/research/amc-entertainment-stock-buy-now/?src=A00220\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMC":"AMC院线"},"source_url":"https://www.investors.com/research/amc-entertainment-stock-buy-now/?src=A00220","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1104186500","content_text":"Going to the movies is exciting. But can it match the action by AMC Entertainment(AMC)? Starting the year at 2 a share,AMC stock skyrocketed more than 36-foldto an all-time high of 72.62 on June 2.\nEven though an epic short squeeze rally hit overdrive in January this year, AMC stock still attracts short sellers.\nData frombrokerage TradeZero Americafor the week ended July 23 shows AMC Entertainment placed 3rd among stocks trading at least $10 a share and getting sold short the most. A total 14,666 short-sale trades crossed TradeZero's platform at an average price of 38.18 per share. AMC ranked No. 2 for the weeks ended Aug. 20 and Aug. 27; in the most recent week, the broker executed 21,746 trades at an average price of 42.57 per share.\nFor weeks, AMC has faced stubborn upside resistance at the21-day exponential moving average. No longer. During the week ended Aug. 27, shares bolted as much as 40% higher for the week before settling for an 18% gain.\nMore than 694 million shares exchanged hands during the week, the highest since the week ended June 18.\nWith August about to end, AMC shares look well poised to rise four weeks in a row and avoid a two-month slide after the company smashed second-quarter estimates; its net loss of 71 cents a share beat an estimated net loss of 93 cents. Sales rebounded to $444.7 million vs. $18.9 million a year ago, blasting a forecast for $375 million.\nQ2 Reaction\nIn an Aug. 9 news release, AMC Chairman and CEO Adam Aron noted the company raised another $1.25 billion in new equity capital during the quarter; welcomed more than 22 million guests back to its theaters across the globe; and saw successive new pandemic-era box office records on the back of new blockbuster films released over the three-month period.\nAMC stock staged a negative reversal the next day after earnings following an early rally up to its21-day EMA. Please see thisIBD news storyfor more details on second-quarter results.\nMeanwhile, check out the downward-sloping50-day moving average, drawn in red in all IBD charts. It no longer lags the stock price. AMC stock had started to live beneath this vital medium-term level of technical support and resistance. But now AMC shares are showing an encouraging rebound back above the 50-day line (or the 10-week moving average on a weekly chart); such a move after a normal breakout from awell-formed basecan present afollow-on entry point.\nAMC Stock: Still A Leader In The Stock Market Today\nSo, given extraordinary gains through late May, is it time to take profits off the table? After all, the May rally displayedelements of a climax run. And now, gains from a recentbuy pointat 14.64 have now shrunk dramatically.\nOr is it a buy now?\nThis story examines fundamental, technical and fund ownership factors to determine if the Leawood, Kan., company with 1,004 theaters and 11,041 screens scores a good probability of making more money for stock traders.\nAfter Memorial Day, AMC jammed nearly 23% higher after the company announced an agreement to sell 8.5 million shares at $27.15 per share to Mudrick Capital. AMC said the proceeds would go toward strategic acquisitions of \"additional theatre leases, as well as investments to enhance the consumer appeal of AMC's existing theatres.\"\nSome of that money could also go toward paying down debt.\nOn June 3, shares at one point fell more than 30% on news the company plans to sell up to 11.55 million shares — or roughly 2.6% of the total common shares outstanding. AMC raised $587 million. On July 6, the company decided toshelve a plan to sell more shares to the public.\nAre The Shorts Covering AMC Stock?\nMeantime, consider this stat: Prior to the giant gain on June 2, over just five sessions of trade (May 24 to 28), AMC obliterated the short sellers by rising as much as 203%. In the week ended June 4, AMC stock almost finished up 100% or more for a second straight week. Incredible.\nEarlier this year, WallStreetBets chat-room traders on Reddit joined in unison in buying shares and bullish call options in AMC stock. They did the same in a band of other companies that had been heavily sold short and struggling.\nWhen a stock shows ahigh level of short interestand is getting bid up, you can almost count on a chain reaction of buying to occur. Why? Short sellers, betting on a decline in the stock, often have to do an about-face. They cover their short position by buying back shares.\nAccording to data analyzed byMarketSmith,short interest— shares sold short by individual and professional investors —  stands at 0.9 times AMC stock's daily average volume of 99 million shares, or roughly 89 million shares. Short interest, in other words, has climbed back to nearly 17% of the stock's entire float. That's down from 21% in the spring.\nThe NYSE publishes data on short sale positions only twice a month. Plus, the short coverage ratio can be skewed by dramatic changes in daily share turnover. The above data also does not consider any shares that may have been sold short in dark pools.\nTheInvestor's Business Daily teamwill keep close watch for any signs that short interest has dropped lately.\nSince late January, AMC stock has followed an extreme zigzag path. Just two weeks after that 20.36 peak, AMC crashed. Shares fell to as low as 5.26. Then came a huge second wave of buying, sending shares back in the low teens.\nWeek to week, the stock (pumping its market value this year to as high as $36 billion on 513 million shares outstanding and a float of 508 million) has lately seen its overall price range narrow. That's good as thenew base formed.\nWill AMC Stock Keep Rallying In The Long Term?\nAMC fans are betting on a turnaround in fortunes. In 2020, AMC lost $16.15 a share. Over the past five quarters, the company's sales have shrunk 22% to as much as 99% vs. year-ago levels. Such results would normally devastate most companies.\nWall Street now expects net losses of $2.85 a share for 2021, a far cry from the unadjusted net loss of $16.15 it suffered last year. And the Street sees net losses shrinking further in 2022, to 83 cents a share. Recently, that estimate stood at a net loss of 96 cents.\nWith big sales expected to arrive, you can expect cash flows to greatly improve.\nSome observers have expressed concern over the company's debt load ($5.5 billion in borrowings due one year from now or longer, as of June 30) vs. total assets ($11.3 billion) on the balance sheet. While the company generated $1.21 billion in net cash from financing activities in the first six months of 2021, AMC still posted a negative free cash flow of -$252 million. Operating cash flow was a net outflow of $234 million.\nKey IBD Ratings\nThe last time AMC paid a dividend came on March 23, 2020, at 3 cents per common share. If the company were to resume this cash payout, shareholders could attain an annualized 0.9% yield at the current price near 14 a share.\nFor now, AMC scores poorly in many of IBD's proprietary ratings. They include an improved 44Earnings Per Share Ratingon a scale of 1 to 99; an improved yet still weak D for Sales + Profit Margins + Return on Equity (SMR) Rating; and a rising 64Composite Rating on a scale of 1 (wizened) to 99 (wizardly).\nMeanwhile, AMC's movies industry group has dropped deep back into the bottom half of IBD's197 industry groupsin terms of six-month price-weighted performance. Mutual funds owning a stake in AMC have recently risen to as high as 232 at the end of the June-ended quarter vs. 186 in Q4 of 2020. Some portfolio managers are clearly eager to accumulate shares.\nYou can check the daily price-weighted performance of all IBD industry groups, as well as the rankings based on six-month performance, atIBD Data Tables.\nAMC Stock Forecast\nWhen choosing growth stocks for the biggest potential gains based on theCAN SLIM investment paradigm, your chances of finding a true market leader improve when you focus on those with aComposite Ratingof 90 or higher. Shooting for a 95 or higher, particularly at the start of a new bull market, is even better.\nHowever, given that AMC stock is a turnaround play, it makes sense to place more emphasis on relative strength. AMC has that in spades.\nA 99Relative Strength Ratingon a scale of 1 to 99 means that the company has outperformed 99% of all stocks in the IBD database over the past 12 months. Strong long-term performance? Indeed.The Accumulation/Distribution Rating, meanwhile, shows an excellent A grade on a scale of A to E.\nOn the weekly chart and inMarketSmith, watch for therelative strength lineto rise again after falling steeply. The RS line, drawn in blue, compares a stock or ETF's moves vs. the S&P 500. When a stock breaks out of anew base, prefer to see the RS line also running to new high ground. This means that a stock is now outperforming the general market.\nEarlier this year, AMC created a boxy cup-like base over a period of two months. That's plenty of time for asolid cup patternto form. This pattern produces aproper buy pointof 10 cents above the cup's left-side peak of 14.54 on March 18. So in AMC stock's case, thecorrect entrystood at 14.64. You want to see heavy volume on the breakout.\nConclusion: Is It A Buy Now? Or A Sell?\nIn effect,AMC stockstaged astrong breakouttwice over a short period in May.\nFirst, AMC had to surpass 14.64 before becoming a new buy. A 20% gain on May 25 sent shares zooming past theproper buy point. The5% buy zonegoes up to 15.37, so the stock quickly got extended.\nAs always, control your risk. Not all breakouts work, especially when thestock market uptrend goes under pressure or into a correction. The best time to buy? When IBD notes the stock market in aconfirmed uptrend, it signifies that buying demand is healthy among institutional investors.\nIn stock investing, you want the wind at your back, not in your face.\nBack in May, this story suggested keeping a close eye on how AMC stock handles potential upside resistance near 20. In fact, the action since that incredible week ended Jan. 29 could also be viewed as adeep cup pattern. From that vantage point, AMC delivered a second breakout on May 27, surpassing a new 20.46buy pointwith fury.\nTo get this ideal entry in acup without handle, simply add 10 cents to the cup's left-side high — in this case, 20.36. On May 27, shares rifled past this entry. For a while, AMC refused to look back. Still, with gains of as much as 501% in just two weeks, it made sense to lock in at least partial profits.\nAMC Action Today\nAMC had fallen as much as 60% below its 72.62 all-time high. So it does not yet trade at anIBD-style entry point. For those who want to go long, you can watch to see if anew bullish chart patternwill form. For a while, the action began to resemble a rarehigh, tight flag. No longer.\nThe current attempt to rebound back above the 10-week moving average, around 39, sparks a newfollow-on buy opportunityfor the intrepid investor.\nHowever, all in all, AMC is not yet a buy. That could change if shares continue to rally further above the 10-week line with strength and serious volume. Nearly  three months since the peak, it is looking more likely that AMC is building anew base, such as thecup without handle.\nAnd it perhaps will need at least a couple weeks for AMC to build theright side of that new base in bullish fashion.\nFinally, after you buy any stock with solid prospects, always heedthe golden rule of investing. Keeping your losses small keeps you in the investing game for the long haul.","news_type":1},"isVote":1,"tweetType":1,"viewCount":439,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":882372145,"gmtCreate":1631664510387,"gmtModify":1676530602354,"author":{"id":"4088497713200830","authorId":"4088497713200830","name":"skxrena","avatar":"https://static.tigerbbs.com/bcd0597b7a18627a33a524d8ac6dd51d","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4088497713200830","authorIdStr":"4088497713200830"},"themes":[],"htmlText":"go go go","listText":"go go go","text":"go go go","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/882372145","repostId":"2167568176","repostType":4,"isVote":1,"tweetType":1,"viewCount":408,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":146552421,"gmtCreate":1626093158163,"gmtModify":1703753170396,"author":{"id":"4088497713200830","authorId":"4088497713200830","name":"skxrena","avatar":"https://static.tigerbbs.com/bcd0597b7a18627a33a524d8ac6dd51d","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4088497713200830","authorIdStr":"4088497713200830"},"themes":[],"htmlText":"good","listText":"good","text":"good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/146552421","repostId":"1156961347","repostType":4,"repost":{"id":"1156961347","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1626091932,"share":"https://ttm.financial/m/news/1156961347?lang=&edition=fundamental","pubTime":"2021-07-12 20:12","market":"us","language":"en","title":"Toplines Before US Market Open on Monday","url":"https://stock-news.laohu8.com/highlight/detail?id=1156961347","media":"Tiger Newspress","summary":"Futures tracking the Dow and the S&P 500 indexes edged lower on Monday after Wall Street rallied to ","content":"<p>Futures tracking the Dow and the S&amp;P 500 indexes edged lower on Monday after Wall Street rallied to new peaks in the previous session, with investors awaiting the start of the second-quarter earning season and a batch of economic data.</p>\n<p>At 8:10 a.m. ET, Dow E-minis were down 122 points, or 0.35%, S&amp;P 500 E-minis were down 7.5 points, or 0.17% and Nasdaq 100 E-minis were up 33.25 points, or 0.22%.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/ac31dda4d4d95330be5d71b8180102d4\" tg-width=\"810\" tg-height=\"265\" referrerpolicy=\"no-referrer\"><span>*Source From Tiger Trade, EST 08:10</span></p>\n<p>Starting Tuesday, earnings reports are due from JPMorgan Chase, Goldman Sachs, Bank of America and other big banks, with market participants looking for early clues on the economy and stocks tied to growth.</p>\n<p>Shares of the big lenders fell between 0.9% and 1.0% in premarket trading.</p>\n<p>Second-quarter earnings for S&amp;P 500 companies are expected to rise 65.8%, according to IBES data from Refinitiv.</p>\n<p><b>Stocks making the biggest moves in the premarket:</b></p>\n<p><b><a href=\"https://laohu8.com/S/SPCE\">Virgin Galactic</a> — </b>Shares of the space company jumped 9% in premarket trading after CEO Richard Branson completed a long-awaited test flight to space on Sunday.It was the first spaceflight to date for Virgin Galactic carrying more than one passenger. Branson also became the first of the billionaire space company founders to ride his own spacecraft, beating Elon Musk and Jeff Bezos.</p>\n<p><b><a href=\"https://laohu8.com/S/CAKE\">Cheesecake Factory</a></b> <b>—</b> The restaurant stock climbed more than 1% in premarket trading after Raymond Jamesupgraded the shares to outperform from market perform. The Wall Street firm said the market is underestimating the comeback for full-service restaurants. Cheesecake Factory shares have fallen about 8% in the past month.</p>\n<p><b><a href=\"https://laohu8.com/S/JWN\">Nordstrom</a></b> <b>— </b>Shares of the department store dipped slightly after the company said Sundayit has acquired a minority stakein four apparel brands owned by the online U.K. fashion house Asos. The brands — Topshop, Topman, Miss Selfridge and the activewear label HIIT — target younger consumers in their 20s. Financial terms of the deal weren't disclosed.</p>\n<p><b><a href=\"https://laohu8.com/S/JPM\">JPMorgan Chase</a></b> <b>,<a href=\"https://laohu8.com/S/BAC\">Bank of America</a> — </b>Major bank stocks traded lower across the board despite expectations for strong earnings reports this week. JPMorgan dipped 0.7%, while Goldman Sachs fell 0.5% and Bank of America shares traded 0.8% lower. The decline came as bond yields continued to drift lower. JPMorgan and&nbsp;Goldman Sachs&nbsp;kick off earnings season with results due out before the bell on Tuesday.&nbsp;Bank of America,&nbsp;Citigroup and&nbsp;Wells Fargo report on Wednesday.</p>\n<p><b><a href=\"https://laohu8.com/S/UAL\">United Continental</a></b> <b>,<a href=\"https://laohu8.com/S/CCL\">Carnival</a> —</b>Shares tied to the economic reopening were slightly weaker in premarket Monday. United Airline fell more than 1% after losing 2.3% month to date. Boeing and Delta Air Line both traded about 1% lower. Carnival, Norwegian Cruise Line and Royal Caribbean all fell over 1%.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Toplines Before US Market Open on Monday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nToplines Before US Market Open on Monday\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-07-12 20:12</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Futures tracking the Dow and the S&amp;P 500 indexes edged lower on Monday after Wall Street rallied to new peaks in the previous session, with investors awaiting the start of the second-quarter earning season and a batch of economic data.</p>\n<p>At 8:10 a.m. ET, Dow E-minis were down 122 points, or 0.35%, S&amp;P 500 E-minis were down 7.5 points, or 0.17% and Nasdaq 100 E-minis were up 33.25 points, or 0.22%.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/ac31dda4d4d95330be5d71b8180102d4\" tg-width=\"810\" tg-height=\"265\" referrerpolicy=\"no-referrer\"><span>*Source From Tiger Trade, EST 08:10</span></p>\n<p>Starting Tuesday, earnings reports are due from JPMorgan Chase, Goldman Sachs, Bank of America and other big banks, with market participants looking for early clues on the economy and stocks tied to growth.</p>\n<p>Shares of the big lenders fell between 0.9% and 1.0% in premarket trading.</p>\n<p>Second-quarter earnings for S&amp;P 500 companies are expected to rise 65.8%, according to IBES data from Refinitiv.</p>\n<p><b>Stocks making the biggest moves in the premarket:</b></p>\n<p><b><a href=\"https://laohu8.com/S/SPCE\">Virgin Galactic</a> — </b>Shares of the space company jumped 9% in premarket trading after CEO Richard Branson completed a long-awaited test flight to space on Sunday.It was the first spaceflight to date for Virgin Galactic carrying more than one passenger. Branson also became the first of the billionaire space company founders to ride his own spacecraft, beating Elon Musk and Jeff Bezos.</p>\n<p><b><a href=\"https://laohu8.com/S/CAKE\">Cheesecake Factory</a></b> <b>—</b> The restaurant stock climbed more than 1% in premarket trading after Raymond Jamesupgraded the shares to outperform from market perform. The Wall Street firm said the market is underestimating the comeback for full-service restaurants. Cheesecake Factory shares have fallen about 8% in the past month.</p>\n<p><b><a href=\"https://laohu8.com/S/JWN\">Nordstrom</a></b> <b>— </b>Shares of the department store dipped slightly after the company said Sundayit has acquired a minority stakein four apparel brands owned by the online U.K. fashion house Asos. The brands — Topshop, Topman, Miss Selfridge and the activewear label HIIT — target younger consumers in their 20s. Financial terms of the deal weren't disclosed.</p>\n<p><b><a href=\"https://laohu8.com/S/JPM\">JPMorgan Chase</a></b> <b>,<a href=\"https://laohu8.com/S/BAC\">Bank of America</a> — </b>Major bank stocks traded lower across the board despite expectations for strong earnings reports this week. JPMorgan dipped 0.7%, while Goldman Sachs fell 0.5% and Bank of America shares traded 0.8% lower. The decline came as bond yields continued to drift lower. JPMorgan and&nbsp;Goldman Sachs&nbsp;kick off earnings season with results due out before the bell on Tuesday.&nbsp;Bank of America,&nbsp;Citigroup and&nbsp;Wells Fargo report on Wednesday.</p>\n<p><b><a href=\"https://laohu8.com/S/UAL\">United Continental</a></b> <b>,<a href=\"https://laohu8.com/S/CCL\">Carnival</a> —</b>Shares tied to the economic reopening were slightly weaker in premarket Monday. United Airline fell more than 1% after losing 2.3% month to date. Boeing and Delta Air Line both traded about 1% lower. Carnival, Norwegian Cruise Line and Royal Caribbean all fell over 1%.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".DJI":"道琼斯","JWN":"诺德斯特龙","BAC":"美国银行",".IXIC":"NASDAQ Composite","UAL":"联合大陆航空","JPM":"摩根大通","SPCE":"维珍银河","CAKE":"芝乐坊餐馆",".SPX":"S&P 500 Index","CCL":"嘉年华邮轮"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1156961347","content_text":"Futures tracking the Dow and the S&P 500 indexes edged lower on Monday after Wall Street rallied to new peaks in the previous session, with investors awaiting the start of the second-quarter earning season and a batch of economic data.\nAt 8:10 a.m. ET, Dow E-minis were down 122 points, or 0.35%, S&P 500 E-minis were down 7.5 points, or 0.17% and Nasdaq 100 E-minis were up 33.25 points, or 0.22%.\n*Source From Tiger Trade, EST 08:10\nStarting Tuesday, earnings reports are due from JPMorgan Chase, Goldman Sachs, Bank of America and other big banks, with market participants looking for early clues on the economy and stocks tied to growth.\nShares of the big lenders fell between 0.9% and 1.0% in premarket trading.\nSecond-quarter earnings for S&P 500 companies are expected to rise 65.8%, according to IBES data from Refinitiv.\nStocks making the biggest moves in the premarket:\nVirgin Galactic — Shares of the space company jumped 9% in premarket trading after CEO Richard Branson completed a long-awaited test flight to space on Sunday.It was the first spaceflight to date for Virgin Galactic carrying more than one passenger. Branson also became the first of the billionaire space company founders to ride his own spacecraft, beating Elon Musk and Jeff Bezos.\nCheesecake Factory — The restaurant stock climbed more than 1% in premarket trading after Raymond Jamesupgraded the shares to outperform from market perform. The Wall Street firm said the market is underestimating the comeback for full-service restaurants. Cheesecake Factory shares have fallen about 8% in the past month.\nNordstrom — Shares of the department store dipped slightly after the company said Sundayit has acquired a minority stakein four apparel brands owned by the online U.K. fashion house Asos. The brands — Topshop, Topman, Miss Selfridge and the activewear label HIIT — target younger consumers in their 20s. Financial terms of the deal weren't disclosed.\nJPMorgan Chase ,Bank of America — Major bank stocks traded lower across the board despite expectations for strong earnings reports this week. JPMorgan dipped 0.7%, while Goldman Sachs fell 0.5% and Bank of America shares traded 0.8% lower. The decline came as bond yields continued to drift lower. JPMorgan and Goldman Sachs kick off earnings season with results due out before the bell on Tuesday. Bank of America, Citigroup and Wells Fargo report on Wednesday.\nUnited Continental ,Carnival —Shares tied to the economic reopening were slightly weaker in premarket Monday. United Airline fell more than 1% after losing 2.3% month to date. Boeing and Delta Air Line both traded about 1% lower. Carnival, Norwegian Cruise Line and Royal Caribbean all fell over 1%.","news_type":1},"isVote":1,"tweetType":1,"viewCount":319,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":887905534,"gmtCreate":1631952660528,"gmtModify":1676530677375,"author":{"id":"4088497713200830","authorId":"4088497713200830","name":"skxrena","avatar":"https://static.tigerbbs.com/bcd0597b7a18627a33a524d8ac6dd51d","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4088497713200830","authorIdStr":"4088497713200830"},"themes":[],"htmlText":"booooo","listText":"booooo","text":"booooo","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/887905534","repostId":"2168957763","repostType":4,"repost":{"id":"2168957763","pubTimestamp":1631950800,"share":"https://ttm.financial/m/news/2168957763?lang=&edition=fundamental","pubTime":"2021-09-18 15:40","market":"us","language":"en","title":"FDA Advisory Committee Votes Unanimously in Favor of COMIRNATY® Booster for Emergency Use in People 65 and Older and Certain High-Risk Populations","url":"https://stock-news.laohu8.com/highlight/detail?id=2168957763","media":"StreetInsider","summary":"Committee reviewed clinical data showing a booster dose of COMIRNATY® elicits high neutralization ti","content":"<ul>\n <li><i>Committee reviewed clinical data showing a booster dose of COMIRNATY® elicits high neutralization titers against SARS-CoV-2 and all currently tested variants </i></li>\n <li><i>Reactogenicity profile within seven days of the booster dose was typically mild to moderate, with frequency of reactions similar to or lower than after the primary vaccination series</i></li>\n <li><i>Real-world data presented by Israel Ministry of Health show additional protection after receiving a</i> <i>booster translated to vaccine effectiveness comparable to levels seen early in the country’s vaccine</i> <i>rollout</i></li>\n <li><i>FDA expected to make its decision in the coming days </i></li>\n</ul>\n<p><b>NEW YORK AND MAINZ, GERMANY, September 17, 2021</b>—Pfizer Inc. (NYSE: PFE) and <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> (Nasdaq: BNTX) announced today that the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted unanimously to recommend the FDA grant Emergency Use Authorization (EUA) for a booster dose of COMIRNATY® (COVID-19 Vaccine, mRNA) in individuals 65 years of age and older and individuals at high risk of severe COVID-19. The committee recommended that the additional dose be administered at least six months after the two-dose series. The panel also agreed that healthcare workers and others at high risk for occupational exposure should be included in this EUA.</p>\n<p>VRBPAC is made up of independent experts who advise the FDA on scientific and regulatory matters, including the evaluation of vaccine safety and efficacy.</p>\n<p>At this time, VRBPAC did not vote in favor of approval of a booster dose for the full population for which Pfizer and BioNTech submitted their supplemental Biologics License Application, which was individuals 16 and older. The same data have recently been submitted to the European Medicines Agency (EMA) and will be filed with other regulatory authorities in the coming weeks. The companies remain vigilant and continue to generate relevant COMIRNATY booster dose data for evaluation for future licensure in further groups as well as to address emerging variants of concern.</p>\n<p>The FDA is expected to make its decision in the coming days. This decision could allow COMIRNATY to be the first COVID-19 vaccine with a booster authorized in the U.S.</p>\n<p>“Today the VRBPAC reviewed data from our clinical program showing a favorable safety profile and strong immune responses against SARS-CoV-2 after a booster dose of our vaccine. These data, and the larger body of scientific evidence presented at the meeting, underscore our belief that boosters can be a critical tool in the ongoing effort to control the spread of this virus,” said <b>Kathrin U. Jansen, Ph.D., Senior Vice President and Head of Vaccine Research &amp; Development, Pfizer</b>. “We thank the committee for their thoughtful review of the data and will work with the FDA following today’s meeting to address the committee’s questions, as we continue to believe in the benefits of a booster dose for a broader population.”</p>\n<p>“We are committed to support the ongoing efforts to reduce infections and COVID-19 cases. The data we submitted to the FDA, EMA and other regulatory authorities underline that a booster induces a strong immune response against all tested variants of concern and may contribute to address a public health need,” said <b>Özlem Türeci, M.D., Co-founder and Chief Medical Officer of BioNTech.</b></p>\n<p>VRBPAC based its recommendation on the totality of scientific evidence shared by the companies, including data from their clinical program evaluating the safety, tolerability and immunogenicity of a booster dose of COMIRNATY. A booster dose of the vaccine elicited significantly higher neutralizing antibody titers against the initial SARS-CoV-2 virus (wild type), as well as the Beta and Delta variants, when compared with the levels observed after the two-dose primary series. The reactogenicity profile within seven days after the booster dose was typically mild to moderate, and the frequency of reactions was similar to or lower than after dose two. The adverse event profile was generally consistent with other clinical safety data for COMIRNATY.</p>\n<p>Real-world surveillance data also were presented to the VRBPAC by the Israel Ministry of Health, providing further support for the public health impact of boosters. The data presented from Israel included an analysis published this week in <i>The New England Journal of Medicine</i>. The analysis comprised approximately 1.1 million individuals ages 60 years and older who were eligible for a booster dose of the vaccine between July 30 through August 31, 2021. No new safety signals were observed, and reported adverse events were lower than those observed after dose two. The analysis showed that a booster dose restored very high levels of protection against COVID-19 infections and severe disease in this period when Delta was the dominant strain. Individuals who received the booster dose were less likely by a factor of 11.3 (95% CI: 10.4, 12.3) to develop a confirmed infection and less likely by a factor of 19.5 (95% CI: 12.9, 29.5) to develop severe illness compared to those who were previously fully vaccinated but did not receive a booster dose. The additional protection after receiving a booster translated to vaccine effectiveness comparable to levels seen early in the country’s vaccine rollout (an estimated 95%), when the Alpha variant was predominant.</p>\n<p>Under the EUA of the Pfizer-BioNTech vaccine in the U.S., a third dose was <u>previously authorized</u> for individuals at least 12 years of age who have undergone solid organ transplant, or who are diagnosed with conditions that are considered to have an equivalent level of immunocompromise. This authorization of a third dose for immunocompromised individuals is separate and distinct from the booster dose reviewed by VRBPAC today. The third dose for immunocompromised individuals is meant to address the fact that these individuals sometimes do not build enough protection after two doses of the vaccine. In contrast, the booster dose recommended today by VRBPAC for EUA refers to an additional dose of the vaccine that is given to those who have built enough protection after the primary two-dose vaccination series, but may have decreased protection over time due to waning of immunity.</p>\n<p>COMIRNATY, which is based on BioNTech’s proprietary mRNA technology, was developed by both BioNTech and Pfizer. BioNTech is the Marketing Authorization Holder in the United States, the European Union, the United Kingdom, Canada and the holder of emergency use authorizations or equivalents in the United States (jointly with Pfizer) and other countries. Submissions to pursue regulatory approvals in those countries where emergency use authorizations or equivalent were initially granted are planned.</p>\n<p><b>U.S. Indication &amp; Authorized Use</b>COMIRNATY® (COVID-19 Vaccine, mRNA) is an FDA-approved COVID-19 vaccine made by Pfizer for BioNTech.</p>\n<ul>\n <li>It is approved as a 2-dose series for prevention of COVID-19 in individuals 16 years of age and older</li>\n <li>It is also authorized under Emergency Use Authorization (EUA) to be administered for emergency use to:</li>\n</ul>\n<p>The Pfizer-BioNTech COVID-19 Vaccine has received EUA from FDA to:</p>\n<ul>\n <li>prevent COVID-19 in individuals 12 years of age and older, and</li>\n <li>provide a third dose to individuals 12 years of age and older who have been determined to have certain kinds of immunocompromise</li>\n</ul>\n<p>The FDA-approved COMIRNATY® (COVID-19 Vaccine, mRNA) and the EUA-authorized Pfizer-BioNTech COVID-19 Vaccine have the same formulation and can be used interchangeably to provide the COVID-19 vaccination series. An individual may be offered either COMIRNATY® (COVID-19 Vaccine, mRNA) or the Pfizer-BioNTech COVID-19 Vaccine to prevent coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2.</p>\n<p><b>EUA Statement</b>This emergency use of the product has not been approved or licensed by FDA, but has been authorized by FDA under an Emergency Use Authorization (EUA) to prevent Coronavirus Disease 2019 (COVID-19) for use in individuals 12 years of age and older; and the emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product under Section 564(b)(1) of the FD&amp;C Act unless the declaration is terminated or authorization revoked sooner.</p>\n<p><b>Important Safety Information</b>Individuals should <b>not</b> get the Pfizer-BioNTech COVID-19 Vaccine if they:</p>\n<ul>\n <li>had a severe allergic reaction after a previous dose of this vaccine</li>\n <li>had a severe allergic reaction to any ingredient of this vaccine</li>\n</ul>\n<p>Individuals should tell the vaccination provider about all of their medical conditions, including if they:</p>\n<ul>\n <li>have any allergies</li>\n <li>have had myocarditis (inflammation of the heart muscle) or pericarditis (inflammation of the lining outside the heart)</li>\n <li>have a fever</li>\n <li>have a bleeding disorder or are on a blood thinner</li>\n <li>are immunocompromised or are on a medicine that affects the immune system</li>\n <li>are pregnant, plan to become pregnant, or are breastfeeding</li>\n <li>have received another COVID-19 vaccine</li>\n <li>have ever fainted in association with an injection</li>\n</ul>\n<p>The vaccine may not protect everyone.</p>\n<p>Side effects reported with the vaccine include:</p>\n<ul>\n <li>There is a remote chance that the vaccine could cause a severe allergic reaction</li>\n <li>Myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the lining outside the heart) have occurred in some people who have received the vaccine. In most of these people, symptoms began within a few days following receipt of the second dose of the vaccine. The chance of having this occur is very low. Individuals should seek medical attention right away if they have any of the following symptoms after receiving the vaccine:</li>\n <li>Side effects that have been reported with the vaccine include:</li>\n <li>These may not be all the possible side effects of the vaccine. Serious and unexpected side effects may occur. The vaccine is still being studied in clinical trials. Call the vaccination provider or healthcare provider about bothersome side effects or side effects that do not go away</li>\n</ul>\n<p>There is no information on the use of the vaccine with other vaccines.</p>\n<p>Patients should always ask their healthcare providers for medical advice about adverse events. Individuals are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit <u>http://www.vaers.hhs.gov</u> or call 1-800-822-7967. In addition, side effects can be reported to Pfizer Inc. at <u>www.pfizersafetyreporting.com</u> or by calling 1-800-438-1985.</p>\n<p>Please <u>click here</u> for full Prescribing Information (16+ years of age). Please <u>click here</u> for Fact Sheet for Vaccination Providers (12+ years of age).</p>\n<p><b>About Pfizer: Breakthroughs That Change Patients’ Lives</b>At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 170 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at <u>www.Pfizer.com</u>. In addition, to learn more, please visit us on <u>www.Pfizer.com</u> and follow us on <a href=\"https://laohu8.com/S/TWTR\">Twitter</a> at <u>@Pfizer</u> and <u>@Pfizer News</u>, <u>LinkedIn</u>, <u>YouTube</u> and like us on <a href=\"https://laohu8.com/S/FB\">Facebook</a> at <u>Facebook.com/Pfizer</u>.</p>\n<p><b>Pfizer Disclosure Notice</b>The information contained in this release is as of September 17, 2021. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.</p>\n<p>This release contains forward-looking information about Pfizer’s efforts to combat COVID-19, the collaboration between BioNTech and Pfizer to develop a COVID-19 vaccine, the BNT162 mRNA vaccine program and COMIRNATY (COVID-19 Vaccine, mRNA) (BNT162b2) (including a potential booster (third) dose and a supplemental Biologics License Application (sBLA) for a potential booster (third) dose of BNT162b2 in individuals 16 years of age and older in the U.S., qualitative assessments of available data, potential benefits, expectations for clinical trials, the anticipated timing of regulatory submissions, regulatory approvals or authorizations and anticipated manufacturing, distribution and supply) involving substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as risks associated with preclinical and clinical data (including the Phase 3 data), including the possibility of unfavorable new preclinical, clinical or safety data and further analyses of existing preclinical, clinical or safety data; whether and when our Phase 3 clinical trial will demonstrate protection from infection or disease following a booster (third) dose, which is the subject of ongoing study; the ability to produce comparable clinical or other results, including the rate of vaccine effectiveness and safety and tolerability profile observed to date, in additional analyses of the Phase 3 trial and additional studies or in larger, more diverse populations following commercialization; the ability of BNT162b2 to prevent COVID-19 caused by emerging virus variants; the risk that more widespread use of the vaccine will lead to new information about efficacy, safety, or other developments, including the risk of additional adverse reactions, some of which may be serious; the risk that preclinical and clinical trial data are subject to differing interpretations and assessments, including during the peer review/publication process, in the scientific community generally, and by regulatory authorities; whether and when additional data from the BNT162 mRNA vaccine program will be published in scientific journal publications and, if so, when and with what modifications and interpretations; whether regulatory authorities will be satisfied with the design of and results from these and any future preclinical and clinical studies; whether and when applications for a potential booster (third) dose will be filed in any other jurisdictions and whether and when other biologics license and/or emergency use authorization applications or amendments to any such applications may be filed in particular jurisdictions for BNT162b2 or any other potential vaccines that may arise from the BNT162 program, and if obtained, whether or when such emergency use authorization or licenses will expire or terminate; whether and when any applications that may be pending or filed for BNT162b2 (including the sBLA for a potential booster (third) dose in the U.S., applications that may be pending or filed for a potential booster (third) dose in other jurisdictions or any requested amendments to the emergency use or conditional marketing authorizations) or other vaccines that may result from the BNT162 program may be approved by particular regulatory authorities, which will depend on myriad factors, including making a determination as to whether the vaccine’s benefits outweigh its known risks and determination of the vaccine’s efficacy and, if approved, whether it will be commercially successful; decisions by regulatory authorities impacting labeling or marketing, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of a vaccine, including development of products or therapies by other companies; disruptions in the relationships between us and our collaboration partners, clinical trial sites or third-party suppliers; the risk that demand for any products may be reduced or no longer exist; risks related to the availability of raw materials to manufacture a vaccine; challenges related to our vaccine’s ultra-low temperature formulation, two-dose schedule and attendant storage, distribution and administration requirements, including risks related to storage and handling after delivery by Pfizer; the risk that we may not be able to successfully develop other vaccine formulations, booster doses or new variant-specific vaccines; the risk that we may not be able to create or scale up manufacturing capacity on a timely basis or maintain access to logistics or supply channels commensurate with global demand for our vaccine, which would negatively impact our ability to supply the estimated numbers of doses of our vaccine within the projected time periods as previously indicated; whether and when additional supply agreements will be reached; uncertainties regarding the ability to obtain recommendations from vaccine advisory or technical committees and other public health authorities and uncertainties regarding the commercial impact of any such recommendations; challenges related to public vaccine confidence or awareness; uncertainties regarding the impact of COVID-19 on Pfizer’s business, operations and financial results; and competitive developments.</p>\n<p>A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results”, as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at <u>www.sec.gov</u> and <u>www.pfizer.com</u>.</p>\n<p><b>About BioNTech</b>Biopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, <a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a>, Bayer Animal Health, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer. For more information, please visit <u>www.BioNTech.de</u>.</p>\n<p><b>BioNTech Forward-looking Statements</b>This press release contains “forward-looking statements” of BioNTech within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include, but may not be limited to, statements concerning: BioNTech’s efforts to combat COVID-19; the collaboration between BioNTech and Pfizer including the program to develop a COVID-19 vaccine and COMIRNATY (COVID-19 Vaccine, mRNA) (BNT162b2) (including a potential booster (third) dose of BNT162b2 in individuals 16 years of age and older in the U.S., a definite submission of a supplemental BLA for a potential booster dose of a variation of BNT162b2 having a modified mRNA sequence in the U.S., a BLA to support potential full FDA approval of BNT162b2 in individuals 12 through 15 years, whether and when applications for a potential booster (third) dose will be filed in any other jurisdictions, qualitative assessments of available data, potential benefits, expectations for clinical trials, the anticipated timing of regulatory submissions, regulatory approvals or authorizations and anticipated manufacturing, distribution and supply); our expectations regarding the potential characteristics of BNT162b2 in our clinical trials and/or in commercial use based on data observations to date; the ability of BNT162b2 to prevent COVID-19 caused by emerging virus variants; the expected time point for additional readouts on efficacy data of BNT162b2 in our clinical trials; the nature of the clinical data, which is subject to ongoing peer review, regulatory review and market interpretation; the timing for submission of data for, or receipt of, any marketing approval or Emergency Use Authorization; our contemplated shipping and storage plan, including our estimated product shelf life at various temperatures; and the ability of BioNTech to supply the quantities of BNT162 to support clinical development and market demand, including our production estimates for 2021. Any forward-looking statements in this press release are based on BioNTech current expectations and beliefs of future events, and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the ability to meet the pre-defined endpoints in clinical trials; competition to create a vaccine for COVID-19; the ability to produce comparable clinical or other results, including our stated rate of vaccine effectiveness and safety and tolerability profile observed to date, in the remainder of the trial or in larger, more diverse populations upon commercialization; the ability to effectively scale our productions capabilities; and other potential difficulties.</p>\n<p>For a discussion of these and other risks and uncertainties, see BioNTech’s Annual Report as Form 20-F for the Year Ended December 31, 2020, filed with the SEC on March 30, 2021, which is available on the SEC’s website at <u>www.sec.gov</u>. All information in this press release is as of the date of the release, and BioNTech undertakes no duty to update this information unless required by law.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>FDA Advisory Committee Votes Unanimously in Favor of COMIRNATY® Booster for Emergency Use in People 65 and Older and Certain High-Risk Populations</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFDA Advisory Committee Votes Unanimously in Favor of COMIRNATY® Booster for Emergency Use in People 65 and Older and Certain High-Risk Populations\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-18 15:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=18955632><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Committee reviewed clinical data showing a booster dose of COMIRNATY® elicits high neutralization titers against SARS-CoV-2 and all currently tested variants \nReactogenicity profile within seven days ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=18955632\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://www.streetinsider.com/dr/news.php?id=18955632","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2168957763","content_text":"Committee reviewed clinical data showing a booster dose of COMIRNATY® elicits high neutralization titers against SARS-CoV-2 and all currently tested variants \nReactogenicity profile within seven days of the booster dose was typically mild to moderate, with frequency of reactions similar to or lower than after the primary vaccination series\nReal-world data presented by Israel Ministry of Health show additional protection after receiving a booster translated to vaccine effectiveness comparable to levels seen early in the country’s vaccine rollout\nFDA expected to make its decision in the coming days \n\nNEW YORK AND MAINZ, GERMANY, September 17, 2021—Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced today that the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted unanimously to recommend the FDA grant Emergency Use Authorization (EUA) for a booster dose of COMIRNATY® (COVID-19 Vaccine, mRNA) in individuals 65 years of age and older and individuals at high risk of severe COVID-19. The committee recommended that the additional dose be administered at least six months after the two-dose series. The panel also agreed that healthcare workers and others at high risk for occupational exposure should be included in this EUA.\nVRBPAC is made up of independent experts who advise the FDA on scientific and regulatory matters, including the evaluation of vaccine safety and efficacy.\nAt this time, VRBPAC did not vote in favor of approval of a booster dose for the full population for which Pfizer and BioNTech submitted their supplemental Biologics License Application, which was individuals 16 and older. The same data have recently been submitted to the European Medicines Agency (EMA) and will be filed with other regulatory authorities in the coming weeks. The companies remain vigilant and continue to generate relevant COMIRNATY booster dose data for evaluation for future licensure in further groups as well as to address emerging variants of concern.\nThe FDA is expected to make its decision in the coming days. This decision could allow COMIRNATY to be the first COVID-19 vaccine with a booster authorized in the U.S.\n“Today the VRBPAC reviewed data from our clinical program showing a favorable safety profile and strong immune responses against SARS-CoV-2 after a booster dose of our vaccine. These data, and the larger body of scientific evidence presented at the meeting, underscore our belief that boosters can be a critical tool in the ongoing effort to control the spread of this virus,” said Kathrin U. Jansen, Ph.D., Senior Vice President and Head of Vaccine Research & Development, Pfizer. “We thank the committee for their thoughtful review of the data and will work with the FDA following today’s meeting to address the committee’s questions, as we continue to believe in the benefits of a booster dose for a broader population.”\n“We are committed to support the ongoing efforts to reduce infections and COVID-19 cases. The data we submitted to the FDA, EMA and other regulatory authorities underline that a booster induces a strong immune response against all tested variants of concern and may contribute to address a public health need,” said Özlem Türeci, M.D., Co-founder and Chief Medical Officer of BioNTech.\nVRBPAC based its recommendation on the totality of scientific evidence shared by the companies, including data from their clinical program evaluating the safety, tolerability and immunogenicity of a booster dose of COMIRNATY. A booster dose of the vaccine elicited significantly higher neutralizing antibody titers against the initial SARS-CoV-2 virus (wild type), as well as the Beta and Delta variants, when compared with the levels observed after the two-dose primary series. The reactogenicity profile within seven days after the booster dose was typically mild to moderate, and the frequency of reactions was similar to or lower than after dose two. The adverse event profile was generally consistent with other clinical safety data for COMIRNATY.\nReal-world surveillance data also were presented to the VRBPAC by the Israel Ministry of Health, providing further support for the public health impact of boosters. The data presented from Israel included an analysis published this week in The New England Journal of Medicine. The analysis comprised approximately 1.1 million individuals ages 60 years and older who were eligible for a booster dose of the vaccine between July 30 through August 31, 2021. No new safety signals were observed, and reported adverse events were lower than those observed after dose two. The analysis showed that a booster dose restored very high levels of protection against COVID-19 infections and severe disease in this period when Delta was the dominant strain. Individuals who received the booster dose were less likely by a factor of 11.3 (95% CI: 10.4, 12.3) to develop a confirmed infection and less likely by a factor of 19.5 (95% CI: 12.9, 29.5) to develop severe illness compared to those who were previously fully vaccinated but did not receive a booster dose. The additional protection after receiving a booster translated to vaccine effectiveness comparable to levels seen early in the country’s vaccine rollout (an estimated 95%), when the Alpha variant was predominant.\nUnder the EUA of the Pfizer-BioNTech vaccine in the U.S., a third dose was previously authorized for individuals at least 12 years of age who have undergone solid organ transplant, or who are diagnosed with conditions that are considered to have an equivalent level of immunocompromise. This authorization of a third dose for immunocompromised individuals is separate and distinct from the booster dose reviewed by VRBPAC today. The third dose for immunocompromised individuals is meant to address the fact that these individuals sometimes do not build enough protection after two doses of the vaccine. In contrast, the booster dose recommended today by VRBPAC for EUA refers to an additional dose of the vaccine that is given to those who have built enough protection after the primary two-dose vaccination series, but may have decreased protection over time due to waning of immunity.\nCOMIRNATY, which is based on BioNTech’s proprietary mRNA technology, was developed by both BioNTech and Pfizer. BioNTech is the Marketing Authorization Holder in the United States, the European Union, the United Kingdom, Canada and the holder of emergency use authorizations or equivalents in the United States (jointly with Pfizer) and other countries. Submissions to pursue regulatory approvals in those countries where emergency use authorizations or equivalent were initially granted are planned.\nU.S. Indication & Authorized UseCOMIRNATY® (COVID-19 Vaccine, mRNA) is an FDA-approved COVID-19 vaccine made by Pfizer for BioNTech.\n\nIt is approved as a 2-dose series for prevention of COVID-19 in individuals 16 years of age and older\nIt is also authorized under Emergency Use Authorization (EUA) to be administered for emergency use to:\n\nThe Pfizer-BioNTech COVID-19 Vaccine has received EUA from FDA to:\n\nprevent COVID-19 in individuals 12 years of age and older, and\nprovide a third dose to individuals 12 years of age and older who have been determined to have certain kinds of immunocompromise\n\nThe FDA-approved COMIRNATY® (COVID-19 Vaccine, mRNA) and the EUA-authorized Pfizer-BioNTech COVID-19 Vaccine have the same formulation and can be used interchangeably to provide the COVID-19 vaccination series. An individual may be offered either COMIRNATY® (COVID-19 Vaccine, mRNA) or the Pfizer-BioNTech COVID-19 Vaccine to prevent coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2.\nEUA StatementThis emergency use of the product has not been approved or licensed by FDA, but has been authorized by FDA under an Emergency Use Authorization (EUA) to prevent Coronavirus Disease 2019 (COVID-19) for use in individuals 12 years of age and older; and the emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product under Section 564(b)(1) of the FD&C Act unless the declaration is terminated or authorization revoked sooner.\nImportant Safety InformationIndividuals should not get the Pfizer-BioNTech COVID-19 Vaccine if they:\n\nhad a severe allergic reaction after a previous dose of this vaccine\nhad a severe allergic reaction to any ingredient of this vaccine\n\nIndividuals should tell the vaccination provider about all of their medical conditions, including if they:\n\nhave any allergies\nhave had myocarditis (inflammation of the heart muscle) or pericarditis (inflammation of the lining outside the heart)\nhave a fever\nhave a bleeding disorder or are on a blood thinner\nare immunocompromised or are on a medicine that affects the immune system\nare pregnant, plan to become pregnant, or are breastfeeding\nhave received another COVID-19 vaccine\nhave ever fainted in association with an injection\n\nThe vaccine may not protect everyone.\nSide effects reported with the vaccine include:\n\nThere is a remote chance that the vaccine could cause a severe allergic reaction\nMyocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the lining outside the heart) have occurred in some people who have received the vaccine. In most of these people, symptoms began within a few days following receipt of the second dose of the vaccine. The chance of having this occur is very low. Individuals should seek medical attention right away if they have any of the following symptoms after receiving the vaccine:\nSide effects that have been reported with the vaccine include:\nThese may not be all the possible side effects of the vaccine. Serious and unexpected side effects may occur. The vaccine is still being studied in clinical trials. Call the vaccination provider or healthcare provider about bothersome side effects or side effects that do not go away\n\nThere is no information on the use of the vaccine with other vaccines.\nPatients should always ask their healthcare providers for medical advice about adverse events. Individuals are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit http://www.vaers.hhs.gov or call 1-800-822-7967. In addition, side effects can be reported to Pfizer Inc. at www.pfizersafetyreporting.com or by calling 1-800-438-1985.\nPlease click here for full Prescribing Information (16+ years of age). Please click here for Fact Sheet for Vaccination Providers (12+ years of age).\nAbout Pfizer: Breakthroughs That Change Patients’ LivesAt Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 170 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.Pfizer.com. In addition, to learn more, please visit us on www.Pfizer.com and follow us on Twitter at @Pfizer and @Pfizer News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer.\nPfizer Disclosure NoticeThe information contained in this release is as of September 17, 2021. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.\nThis release contains forward-looking information about Pfizer’s efforts to combat COVID-19, the collaboration between BioNTech and Pfizer to develop a COVID-19 vaccine, the BNT162 mRNA vaccine program and COMIRNATY (COVID-19 Vaccine, mRNA) (BNT162b2) (including a potential booster (third) dose and a supplemental Biologics License Application (sBLA) for a potential booster (third) dose of BNT162b2 in individuals 16 years of age and older in the U.S., qualitative assessments of available data, potential benefits, expectations for clinical trials, the anticipated timing of regulatory submissions, regulatory approvals or authorizations and anticipated manufacturing, distribution and supply) involving substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as risks associated with preclinical and clinical data (including the Phase 3 data), including the possibility of unfavorable new preclinical, clinical or safety data and further analyses of existing preclinical, clinical or safety data; whether and when our Phase 3 clinical trial will demonstrate protection from infection or disease following a booster (third) dose, which is the subject of ongoing study; the ability to produce comparable clinical or other results, including the rate of vaccine effectiveness and safety and tolerability profile observed to date, in additional analyses of the Phase 3 trial and additional studies or in larger, more diverse populations following commercialization; the ability of BNT162b2 to prevent COVID-19 caused by emerging virus variants; the risk that more widespread use of the vaccine will lead to new information about efficacy, safety, or other developments, including the risk of additional adverse reactions, some of which may be serious; the risk that preclinical and clinical trial data are subject to differing interpretations and assessments, including during the peer review/publication process, in the scientific community generally, and by regulatory authorities; whether and when additional data from the BNT162 mRNA vaccine program will be published in scientific journal publications and, if so, when and with what modifications and interpretations; whether regulatory authorities will be satisfied with the design of and results from these and any future preclinical and clinical studies; whether and when applications for a potential booster (third) dose will be filed in any other jurisdictions and whether and when other biologics license and/or emergency use authorization applications or amendments to any such applications may be filed in particular jurisdictions for BNT162b2 or any other potential vaccines that may arise from the BNT162 program, and if obtained, whether or when such emergency use authorization or licenses will expire or terminate; whether and when any applications that may be pending or filed for BNT162b2 (including the sBLA for a potential booster (third) dose in the U.S., applications that may be pending or filed for a potential booster (third) dose in other jurisdictions or any requested amendments to the emergency use or conditional marketing authorizations) or other vaccines that may result from the BNT162 program may be approved by particular regulatory authorities, which will depend on myriad factors, including making a determination as to whether the vaccine’s benefits outweigh its known risks and determination of the vaccine’s efficacy and, if approved, whether it will be commercially successful; decisions by regulatory authorities impacting labeling or marketing, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of a vaccine, including development of products or therapies by other companies; disruptions in the relationships between us and our collaboration partners, clinical trial sites or third-party suppliers; the risk that demand for any products may be reduced or no longer exist; risks related to the availability of raw materials to manufacture a vaccine; challenges related to our vaccine’s ultra-low temperature formulation, two-dose schedule and attendant storage, distribution and administration requirements, including risks related to storage and handling after delivery by Pfizer; the risk that we may not be able to successfully develop other vaccine formulations, booster doses or new variant-specific vaccines; the risk that we may not be able to create or scale up manufacturing capacity on a timely basis or maintain access to logistics or supply channels commensurate with global demand for our vaccine, which would negatively impact our ability to supply the estimated numbers of doses of our vaccine within the projected time periods as previously indicated; whether and when additional supply agreements will be reached; uncertainties regarding the ability to obtain recommendations from vaccine advisory or technical committees and other public health authorities and uncertainties regarding the commercial impact of any such recommendations; challenges related to public vaccine confidence or awareness; uncertainties regarding the impact of COVID-19 on Pfizer’s business, operations and financial results; and competitive developments.\nA further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results”, as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com.\nAbout BioNTechBiopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer. For more information, please visit www.BioNTech.de.\nBioNTech Forward-looking StatementsThis press release contains “forward-looking statements” of BioNTech within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include, but may not be limited to, statements concerning: BioNTech’s efforts to combat COVID-19; the collaboration between BioNTech and Pfizer including the program to develop a COVID-19 vaccine and COMIRNATY (COVID-19 Vaccine, mRNA) (BNT162b2) (including a potential booster (third) dose of BNT162b2 in individuals 16 years of age and older in the U.S., a definite submission of a supplemental BLA for a potential booster dose of a variation of BNT162b2 having a modified mRNA sequence in the U.S., a BLA to support potential full FDA approval of BNT162b2 in individuals 12 through 15 years, whether and when applications for a potential booster (third) dose will be filed in any other jurisdictions, qualitative assessments of available data, potential benefits, expectations for clinical trials, the anticipated timing of regulatory submissions, regulatory approvals or authorizations and anticipated manufacturing, distribution and supply); our expectations regarding the potential characteristics of BNT162b2 in our clinical trials and/or in commercial use based on data observations to date; the ability of BNT162b2 to prevent COVID-19 caused by emerging virus variants; the expected time point for additional readouts on efficacy data of BNT162b2 in our clinical trials; the nature of the clinical data, which is subject to ongoing peer review, regulatory review and market interpretation; the timing for submission of data for, or receipt of, any marketing approval or Emergency Use Authorization; our contemplated shipping and storage plan, including our estimated product shelf life at various temperatures; and the ability of BioNTech to supply the quantities of BNT162 to support clinical development and market demand, including our production estimates for 2021. Any forward-looking statements in this press release are based on BioNTech current expectations and beliefs of future events, and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the ability to meet the pre-defined endpoints in clinical trials; competition to create a vaccine for COVID-19; the ability to produce comparable clinical or other results, including our stated rate of vaccine effectiveness and safety and tolerability profile observed to date, in the remainder of the trial or in larger, more diverse populations upon commercialization; the ability to effectively scale our productions capabilities; and other potential difficulties.\nFor a discussion of these and other risks and uncertainties, see BioNTech’s Annual Report as Form 20-F for the Year Ended December 31, 2020, filed with the SEC on March 30, 2021, which is available on the SEC’s website at www.sec.gov. All information in this press release is as of the date of the release, and BioNTech undertakes no duty to update this information unless required by law.","news_type":1},"isVote":1,"tweetType":1,"viewCount":68,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":172742406,"gmtCreate":1626996536805,"gmtModify":1703481953029,"author":{"id":"4088497713200830","authorId":"4088497713200830","name":"skxrena","avatar":"https://static.tigerbbs.com/bcd0597b7a18627a33a524d8ac6dd51d","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4088497713200830","authorIdStr":"4088497713200830"},"themes":[],"htmlText":"awesoms","listText":"awesoms","text":"awesoms","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/172742406","repostId":"2153670096","repostType":4,"repost":{"id":"2153670096","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1626996120,"share":"https://ttm.financial/m/news/2153670096?lang=&edition=fundamental","pubTime":"2021-07-23 07:22","market":"us","language":"en","title":"Intel stock ticks lower as outlook barely clears Wall Street expectations following beat","url":"https://stock-news.laohu8.com/highlight/detail?id=2153670096","media":"Dow Jones","summary":"Revenue tops estimates while declining for fourth straight quarter\nIntel Corp. shares weakened in th","content":"<p>Revenue tops estimates while declining for fourth straight quarter</p>\n<p>Intel Corp. shares weakened in the extended session Thursday after the chip maker topped expectations, but its outlook barely surpassed the average forecast from Wall Street analysts.</p>\n<p>Intel <a href=\"https://laohu8.com/S/INTC\">$(INTC)$</a> shares were last down 1% in the extended session, following an initial 3% uptick in after-hours trading. Shares closed down 0.5% in the regular session at $55.96.</p>\n<p>Intel reported second-quarter net income of $5.06 billion, or $1.24 a share, compared with $5.11 billion, or $1.19 a share, in the year-ago period. After adjusting for acquisition-related expenses and other items, Intel reported earnings of $1.28 a share, compared with $1.23 a share from a year ago.</p>\n<p>Revenue declined to $19.63 billion from $19.73 billion in the year-ago quarter, for a fourth straight quarter of year-over-year revenue declines, but topped its own and analysts' estimates. Excluding the company's memory business, revenue was $18.5 billion. Analysts had estimated adjusted earnings of $1.07 a share on revenue of $17.81 billion, while Intel had forecast adjusted earnings of $1.05 a share on revenue of $18.9 billion, or $17.8 billion when removing the memory business it was divesting.</p>\n<p>\"Our second-quarter results show that our momentum is building, our execution is improving, and customers continue to choose us for leadership products,\" said Intel Chief Executive Pat Gelsinger in a statement.</p>\n<p>For the third quarter, Intel forecast revenue of about $19.1 billion, or $18.2 billion when removing the memory business, and GAAP earnings of $1.08 a share and non-GAAP earnings of $1.10 a share. Analysts on average expected adjusted third-quarter earnings of $1.09 a share on revenue of $18.11 billion.</p>\n<p>Intel's data-center group revenue declined 9% to $6.5 billion, while analysts surveyed by FactSet expected $5.84 billion.</p>\n<p>Intel's largest segment -- client-computing, the traditional PC group -- rose 6% to $10.1 billion, with analysts expecting $10.03 billion.</p>\n<p>Intel reported that nonvolatile memory-solutions revenue fell 34% to $1.1 billion, while Wall Street expected $690.8 million, and \"Internet of Things,\" or IoT, revenue rose 47% to $984 million, compared with an expected $901.5 million. <a href=\"https://laohu8.com/S/MBLY\">Mobileye</a> revenue soared 124% to $327 million, but the Street had expected $361.4 million.</p>\n<p>Over the past 12 months, Intel stock has fallen 8%. Over the same period, the Dow Jones Industrial Average -- which counts Intel as a component -- has gained 29%, the S&amp;P 500 index has climbed 33%, the tech-heavy Nasdaq Composite Index has advanced 37%, and the PHLX Semiconductor Index has surged 55%.</p>\n<p>On Wednesday, Texas Instruments Inc. <a href=\"https://laohu8.com/S/TXN\">$(TXN)$</a>kicked off earnings season for U.S. chip makers, amid a global semiconductor shortage.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Intel stock ticks lower as outlook barely clears Wall Street expectations following beat</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIntel stock ticks lower as outlook barely clears Wall Street expectations following beat\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-07-23 07:22</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>Revenue tops estimates while declining for fourth straight quarter</p>\n<p>Intel Corp. shares weakened in the extended session Thursday after the chip maker topped expectations, but its outlook barely surpassed the average forecast from Wall Street analysts.</p>\n<p>Intel <a href=\"https://laohu8.com/S/INTC\">$(INTC)$</a> shares were last down 1% in the extended session, following an initial 3% uptick in after-hours trading. Shares closed down 0.5% in the regular session at $55.96.</p>\n<p>Intel reported second-quarter net income of $5.06 billion, or $1.24 a share, compared with $5.11 billion, or $1.19 a share, in the year-ago period. After adjusting for acquisition-related expenses and other items, Intel reported earnings of $1.28 a share, compared with $1.23 a share from a year ago.</p>\n<p>Revenue declined to $19.63 billion from $19.73 billion in the year-ago quarter, for a fourth straight quarter of year-over-year revenue declines, but topped its own and analysts' estimates. Excluding the company's memory business, revenue was $18.5 billion. Analysts had estimated adjusted earnings of $1.07 a share on revenue of $17.81 billion, while Intel had forecast adjusted earnings of $1.05 a share on revenue of $18.9 billion, or $17.8 billion when removing the memory business it was divesting.</p>\n<p>\"Our second-quarter results show that our momentum is building, our execution is improving, and customers continue to choose us for leadership products,\" said Intel Chief Executive Pat Gelsinger in a statement.</p>\n<p>For the third quarter, Intel forecast revenue of about $19.1 billion, or $18.2 billion when removing the memory business, and GAAP earnings of $1.08 a share and non-GAAP earnings of $1.10 a share. Analysts on average expected adjusted third-quarter earnings of $1.09 a share on revenue of $18.11 billion.</p>\n<p>Intel's data-center group revenue declined 9% to $6.5 billion, while analysts surveyed by FactSet expected $5.84 billion.</p>\n<p>Intel's largest segment -- client-computing, the traditional PC group -- rose 6% to $10.1 billion, with analysts expecting $10.03 billion.</p>\n<p>Intel reported that nonvolatile memory-solutions revenue fell 34% to $1.1 billion, while Wall Street expected $690.8 million, and \"Internet of Things,\" or IoT, revenue rose 47% to $984 million, compared with an expected $901.5 million. <a href=\"https://laohu8.com/S/MBLY\">Mobileye</a> revenue soared 124% to $327 million, but the Street had expected $361.4 million.</p>\n<p>Over the past 12 months, Intel stock has fallen 8%. Over the same period, the Dow Jones Industrial Average -- which counts Intel as a component -- has gained 29%, the S&amp;P 500 index has climbed 33%, the tech-heavy Nasdaq Composite Index has advanced 37%, and the PHLX Semiconductor Index has surged 55%.</p>\n<p>On Wednesday, Texas Instruments Inc. <a href=\"https://laohu8.com/S/TXN\">$(TXN)$</a>kicked off earnings season for U.S. chip makers, amid a global semiconductor shortage.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"03086":"华夏纳指","INTC":"英特尔","09086":"华夏纳指-U"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2153670096","content_text":"Revenue tops estimates while declining for fourth straight quarter\nIntel Corp. shares weakened in the extended session Thursday after the chip maker topped expectations, but its outlook barely surpassed the average forecast from Wall Street analysts.\nIntel $(INTC)$ shares were last down 1% in the extended session, following an initial 3% uptick in after-hours trading. Shares closed down 0.5% in the regular session at $55.96.\nIntel reported second-quarter net income of $5.06 billion, or $1.24 a share, compared with $5.11 billion, or $1.19 a share, in the year-ago period. After adjusting for acquisition-related expenses and other items, Intel reported earnings of $1.28 a share, compared with $1.23 a share from a year ago.\nRevenue declined to $19.63 billion from $19.73 billion in the year-ago quarter, for a fourth straight quarter of year-over-year revenue declines, but topped its own and analysts' estimates. Excluding the company's memory business, revenue was $18.5 billion. Analysts had estimated adjusted earnings of $1.07 a share on revenue of $17.81 billion, while Intel had forecast adjusted earnings of $1.05 a share on revenue of $18.9 billion, or $17.8 billion when removing the memory business it was divesting.\n\"Our second-quarter results show that our momentum is building, our execution is improving, and customers continue to choose us for leadership products,\" said Intel Chief Executive Pat Gelsinger in a statement.\nFor the third quarter, Intel forecast revenue of about $19.1 billion, or $18.2 billion when removing the memory business, and GAAP earnings of $1.08 a share and non-GAAP earnings of $1.10 a share. Analysts on average expected adjusted third-quarter earnings of $1.09 a share on revenue of $18.11 billion.\nIntel's data-center group revenue declined 9% to $6.5 billion, while analysts surveyed by FactSet expected $5.84 billion.\nIntel's largest segment -- client-computing, the traditional PC group -- rose 6% to $10.1 billion, with analysts expecting $10.03 billion.\nIntel reported that nonvolatile memory-solutions revenue fell 34% to $1.1 billion, while Wall Street expected $690.8 million, and \"Internet of Things,\" or IoT, revenue rose 47% to $984 million, compared with an expected $901.5 million. Mobileye revenue soared 124% to $327 million, but the Street had expected $361.4 million.\nOver the past 12 months, Intel stock has fallen 8%. Over the same period, the Dow Jones Industrial Average -- which counts Intel as a component -- has gained 29%, the S&P 500 index has climbed 33%, the tech-heavy Nasdaq Composite Index has advanced 37%, and the PHLX Semiconductor Index has surged 55%.\nOn Wednesday, Texas Instruments Inc. $(TXN)$kicked off earnings season for U.S. chip makers, amid a global semiconductor shortage.","news_type":1},"isVote":1,"tweetType":1,"viewCount":238,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":178281707,"gmtCreate":1626823709009,"gmtModify":1703765744606,"author":{"id":"4088497713200830","authorId":"4088497713200830","name":"skxrena","avatar":"https://static.tigerbbs.com/bcd0597b7a18627a33a524d8ac6dd51d","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4088497713200830","authorIdStr":"4088497713200830"},"themes":[],"htmlText":"great!","listText":"great!","text":"great!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/178281707","repostId":"2153924256","repostType":4,"repost":{"id":"2153924256","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1626812915,"share":"https://ttm.financial/m/news/2153924256?lang=&edition=fundamental","pubTime":"2021-07-21 04:28","market":"us","language":"en","title":"Wall Street bounces back on renewed economic optimism","url":"https://stock-news.laohu8.com/highlight/detail?id=2153924256","media":"Reuters","summary":"NEW YORK, July 20 (Reuters) - Wall Street ended sharply higher on Tuesday, rebounding from a multi-d","content":"<p>NEW YORK, July 20 (Reuters) - Wall Street ended sharply higher on Tuesday, rebounding from a multi-day losing streak as a string of upbeat earnings reports and revived economic optimism fueled a risk-on rally.</p>\n<p>All three major U.S. stock indexes gained more than 1% with the blue-chip Dow, on the heels of its worst day in nine months, leading the charge.</p>\n<p>The S&amp;P notched its first advance in four days as well as registering its strongest day since March. The Nasdaq posted its first gain in six sessions.</p>\n<p>\"It’s a buy-the-dip mentality coming into the market,\" said Chuck Carlson, chief executive officer at Horizon Investment Services in Hammond, Indiana.</p>\n<p>Economically sensitive small caps&nbsp;and transports&nbsp;outperformed the broader market.</p>\n<p>Benchmark U.S. Treasury yields bounced back from five-month lows, in the wake of their biggest single-session decline since February in the prior session . This helped boost rate-vulnerable banks by 2.6%.</p>\n<p>\"The economically sensitive stocks are up today,\" Carlson added. \"When the 10-year (Treasury yield) goes down in a short period of time, that typically doesn’t happen with an economy that’s supposed to be growing. Firming in the 10-year (yield) indicates that perhaps the economy isn’t going to be falling off a cliff.\"</p>\n<p>Mounting concerns over the highly contagious Delta variant of COVID-19, now responsible for the majority of new infections, have sparked sell-offs in recent sessions as worldwide vaccination efforts gather momentum.</p>\n<p>\"Things like the Delta variant can certainly impact in the margins,\" Carlson said. \"It doesn’t take a whole lot of fear in some investors to create what we saw yesterday.\"</p>\n<p>The Dow Jones Industrial Average rose 549.95 points, or 1.62%, to 34,511.99, the S&amp;P 500 gained 64.57 points, or 1.52%, to 4,323.06 and the Nasdaq Composite added 223.89 points, or 1.57%, to 14,498.88.</p>\n<p>Of the 11 major sectors in the S&amp;P 500, all but consumer staples closed green. Industrials fared best, rising 2.7%.</p>\n<p>Second-quarter reporting season has hit full-stride, with 56 of the companies in the S&amp;P 500 having posted results. Of those, 91% have beaten consensus, according to Refinitiv.</p>\n<p>Analysts now see annual S&amp;P earnings growth of 72.9% for the April-June period, a significant improvement over the 54% growth seen at the beginning of the quarter.</p>\n<p>Halliburton Co&nbsp;rose 3.7% after a bounce-back in crude prices boosted oilfield services demand, leading the company to post its second consecutive quarterly profit.</p>\n<p>Peloton Interactive Inc&nbsp;advanced 6.7% after announcing it would provide UnitedHealth Group's fully insured members free access to its live and on-demand fitness classes.</p>\n<p>Moderna's&nbsp;stock dropped 2% in a volatile session on Tuesday, with the COVID-19 vaccine maker the most heavily traded company on Wall Street ahead of its debut in the S&amp;P 500 on Wednesday.</p>\n<p>Netflix Inc&nbsp;shares dipped more than 3% in after- hours trading after its forecast missed estimates.</p>\n<p>Shares of Chipotle Mexican Grill gained over 2% post-market after its earnings and revenue beat consensus.</p>\n<p>Advancing issues outnumbered declining ones on the NYSE by a 4.44-to-1 ratio; on Nasdaq, a 3.59-to-1 ratio favored advancers.</p>\n<p>The S&amp;P 500 posted 41 new 52-week highs and no new lows; the Nasdaq Composite recorded 45 new highs and 76 new lows.</p>\n<p>Volume on U.S. exchanges was 10.62 billion shares, compared with the 10.19 billion average over the last 20 trading days.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Wall Street bounces back on renewed economic optimism</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWall Street bounces back on renewed economic optimism\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-07-21 04:28</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>NEW YORK, July 20 (Reuters) - Wall Street ended sharply higher on Tuesday, rebounding from a multi-day losing streak as a string of upbeat earnings reports and revived economic optimism fueled a risk-on rally.</p>\n<p>All three major U.S. stock indexes gained more than 1% with the blue-chip Dow, on the heels of its worst day in nine months, leading the charge.</p>\n<p>The S&amp;P notched its first advance in four days as well as registering its strongest day since March. The Nasdaq posted its first gain in six sessions.</p>\n<p>\"It’s a buy-the-dip mentality coming into the market,\" said Chuck Carlson, chief executive officer at Horizon Investment Services in Hammond, Indiana.</p>\n<p>Economically sensitive small caps&nbsp;and transports&nbsp;outperformed the broader market.</p>\n<p>Benchmark U.S. Treasury yields bounced back from five-month lows, in the wake of their biggest single-session decline since February in the prior session . This helped boost rate-vulnerable banks by 2.6%.</p>\n<p>\"The economically sensitive stocks are up today,\" Carlson added. \"When the 10-year (Treasury yield) goes down in a short period of time, that typically doesn’t happen with an economy that’s supposed to be growing. Firming in the 10-year (yield) indicates that perhaps the economy isn’t going to be falling off a cliff.\"</p>\n<p>Mounting concerns over the highly contagious Delta variant of COVID-19, now responsible for the majority of new infections, have sparked sell-offs in recent sessions as worldwide vaccination efforts gather momentum.</p>\n<p>\"Things like the Delta variant can certainly impact in the margins,\" Carlson said. \"It doesn’t take a whole lot of fear in some investors to create what we saw yesterday.\"</p>\n<p>The Dow Jones Industrial Average rose 549.95 points, or 1.62%, to 34,511.99, the S&amp;P 500 gained 64.57 points, or 1.52%, to 4,323.06 and the Nasdaq Composite added 223.89 points, or 1.57%, to 14,498.88.</p>\n<p>Of the 11 major sectors in the S&amp;P 500, all but consumer staples closed green. Industrials fared best, rising 2.7%.</p>\n<p>Second-quarter reporting season has hit full-stride, with 56 of the companies in the S&amp;P 500 having posted results. Of those, 91% have beaten consensus, according to Refinitiv.</p>\n<p>Analysts now see annual S&amp;P earnings growth of 72.9% for the April-June period, a significant improvement over the 54% growth seen at the beginning of the quarter.</p>\n<p>Halliburton Co&nbsp;rose 3.7% after a bounce-back in crude prices boosted oilfield services demand, leading the company to post its second consecutive quarterly profit.</p>\n<p>Peloton Interactive Inc&nbsp;advanced 6.7% after announcing it would provide UnitedHealth Group's fully insured members free access to its live and on-demand fitness classes.</p>\n<p>Moderna's&nbsp;stock dropped 2% in a volatile session on Tuesday, with the COVID-19 vaccine maker the most heavily traded company on Wall Street ahead of its debut in the S&amp;P 500 on Wednesday.</p>\n<p>Netflix Inc&nbsp;shares dipped more than 3% in after- hours trading after its forecast missed estimates.</p>\n<p>Shares of Chipotle Mexican Grill gained over 2% post-market after its earnings and revenue beat consensus.</p>\n<p>Advancing issues outnumbered declining ones on the NYSE by a 4.44-to-1 ratio; on Nasdaq, a 3.59-to-1 ratio favored advancers.</p>\n<p>The S&amp;P 500 posted 41 new 52-week highs and no new lows; the Nasdaq Composite recorded 45 new highs and 76 new lows.</p>\n<p>Volume on U.S. exchanges was 10.62 billion shares, compared with the 10.19 billion average over the last 20 trading days.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"161125":"标普500","513500":"标普500ETF","QQQ":"纳指100ETF","SDOW":"道指三倍做空ETF-ProShares","DOG":"道指反向ETF","IVV":"标普500指数ETF","QID":"纳指两倍做空ETF","SH":"标普500反向ETF","NFLX":"奈飞","SSO":"两倍做多标普500ETF","SPXU":"三倍做空标普500ETF","OEF":"标普100指数ETF-iShares","OEX":"标普100","MRNA":"Moderna, Inc.","SQQQ":"纳指三倍做空ETF","QNETCN":"纳斯达克中美互联网老虎指数","DXD":"道指两倍做空ETF","QLD":"纳指两倍做多ETF","UPRO":"三倍做多标普500ETF","PSQ":"纳指反向ETF","UDOW":"道指三倍做多ETF-ProShares","TQQQ":"纳指三倍做多ETF","DDM":"道指两倍做多ETF","SDS":"两倍做空标普500ETF","DJX":"1/100道琼斯"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2153924256","content_text":"NEW YORK, July 20 (Reuters) - Wall Street ended sharply higher on Tuesday, rebounding from a multi-day losing streak as a string of upbeat earnings reports and revived economic optimism fueled a risk-on rally.\nAll three major U.S. stock indexes gained more than 1% with the blue-chip Dow, on the heels of its worst day in nine months, leading the charge.\nThe S&P notched its first advance in four days as well as registering its strongest day since March. The Nasdaq posted its first gain in six sessions.\n\"It’s a buy-the-dip mentality coming into the market,\" said Chuck Carlson, chief executive officer at Horizon Investment Services in Hammond, Indiana.\nEconomically sensitive small caps and transports outperformed the broader market.\nBenchmark U.S. Treasury yields bounced back from five-month lows, in the wake of their biggest single-session decline since February in the prior session . This helped boost rate-vulnerable banks by 2.6%.\n\"The economically sensitive stocks are up today,\" Carlson added. \"When the 10-year (Treasury yield) goes down in a short period of time, that typically doesn’t happen with an economy that’s supposed to be growing. Firming in the 10-year (yield) indicates that perhaps the economy isn’t going to be falling off a cliff.\"\nMounting concerns over the highly contagious Delta variant of COVID-19, now responsible for the majority of new infections, have sparked sell-offs in recent sessions as worldwide vaccination efforts gather momentum.\n\"Things like the Delta variant can certainly impact in the margins,\" Carlson said. \"It doesn’t take a whole lot of fear in some investors to create what we saw yesterday.\"\nThe Dow Jones Industrial Average rose 549.95 points, or 1.62%, to 34,511.99, the S&P 500 gained 64.57 points, or 1.52%, to 4,323.06 and the Nasdaq Composite added 223.89 points, or 1.57%, to 14,498.88.\nOf the 11 major sectors in the S&P 500, all but consumer staples closed green. Industrials fared best, rising 2.7%.\nSecond-quarter reporting season has hit full-stride, with 56 of the companies in the S&P 500 having posted results. Of those, 91% have beaten consensus, according to Refinitiv.\nAnalysts now see annual S&P earnings growth of 72.9% for the April-June period, a significant improvement over the 54% growth seen at the beginning of the quarter.\nHalliburton Co rose 3.7% after a bounce-back in crude prices boosted oilfield services demand, leading the company to post its second consecutive quarterly profit.\nPeloton Interactive Inc advanced 6.7% after announcing it would provide UnitedHealth Group's fully insured members free access to its live and on-demand fitness classes.\nModerna's stock dropped 2% in a volatile session on Tuesday, with the COVID-19 vaccine maker the most heavily traded company on Wall Street ahead of its debut in the S&P 500 on Wednesday.\nNetflix Inc shares dipped more than 3% in after- hours trading after its forecast missed estimates.\nShares of Chipotle Mexican Grill gained over 2% post-market after its earnings and revenue beat consensus.\nAdvancing issues outnumbered declining ones on the NYSE by a 4.44-to-1 ratio; on Nasdaq, a 3.59-to-1 ratio favored advancers.\nThe S&P 500 posted 41 new 52-week highs and no new lows; the Nasdaq Composite recorded 45 new highs and 76 new lows.\nVolume on U.S. exchanges was 10.62 billion shares, compared with the 10.19 billion average over the last 20 trading days.","news_type":1},"isVote":1,"tweetType":1,"viewCount":295,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":145747146,"gmtCreate":1626250091585,"gmtModify":1703756323943,"author":{"id":"4088497713200830","authorId":"4088497713200830","name":"skxrena","avatar":"https://static.tigerbbs.com/bcd0597b7a18627a33a524d8ac6dd51d","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4088497713200830","authorIdStr":"4088497713200830"},"themes":[],"htmlText":"awesome","listText":"awesome","text":"awesome","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/145747146","repostId":"1158281742","repostType":4,"isVote":1,"tweetType":1,"viewCount":565,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}